US8008291B2 - 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists - Google Patents

3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists Download PDF

Info

Publication number
US8008291B2
US8008291B2 US12/391,720 US39172009A US8008291B2 US 8008291 B2 US8008291 B2 US 8008291B2 US 39172009 A US39172009 A US 39172009A US 8008291 B2 US8008291 B2 US 8008291B2
Authority
US
United States
Prior art keywords
diazepan
oxo
methyl
ethyl
naphthamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US12/391,720
Other languages
English (en)
Other versions
US20090221557A1 (en
Inventor
Mark Arnold Thomas Blaskovich
Peter Joseph Cassidy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marp Therapeutics Pty Ltd
Original Assignee
Mimetica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/391,720 priority Critical patent/US8008291B2/en
Application filed by Mimetica Pty Ltd filed Critical Mimetica Pty Ltd
Priority to PCT/AU2009/000230 priority patent/WO2009105823A1/en
Priority to ES09716155.8T priority patent/ES2445456T3/es
Priority to AU2009219106A priority patent/AU2009219106B2/en
Priority to MX2010009487A priority patent/MX2010009487A/es
Priority to EP09716155.8A priority patent/EP2257534B1/en
Priority to DK09716155.8T priority patent/DK2257534T3/da
Priority to JP2010547917A priority patent/JP5503557B2/ja
Priority to CN200980112982.0A priority patent/CN102007105B/zh
Priority to KR1020107021383A priority patent/KR101620114B1/ko
Priority to HK11102369.6A priority patent/HK1148730B/en
Priority to PT97161558T priority patent/PT2257534E/pt
Priority to NZ587363A priority patent/NZ587363A/en
Priority to CA2716250A priority patent/CA2716250C/en
Priority to BRPI0907903-3A priority patent/BRPI0907903B1/pt
Priority to RU2010137034/04A priority patent/RU2530017C2/ru
Publication of US20090221557A1 publication Critical patent/US20090221557A1/en
Priority to IL207700A priority patent/IL207700A/en
Assigned to MIMETICA PTY LTD reassignment MIMETICA PTY LTD ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BLASKOVICH, MARK ARNOLD THOMAS, CASSIDY, PETER JOSEPH
Priority to US13/154,144 priority patent/US8343958B2/en
Application granted granted Critical
Publication of US8008291B2 publication Critical patent/US8008291B2/en
Assigned to Marp Therapeutics Pty Ltd reassignment Marp Therapeutics Pty Ltd ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MIMETICA PTY LTD
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Definitions

  • the present invention relates to the field of melanocortin-5 receptor antagonists.
  • the present invention relates to a family of 1,4-diazepan-2-ones and derivatives thereof that are antagonists of the melanocortin-5 receptor.
  • the invention also relates to pharmaceutical compositions containing these compounds.
  • the melanocortin-5 receptor (MC5R) is a G-protein coupled receptor (GPCR) belonging to the family of melanocortin receptors. There are five melanocortin receptors that have been isolated and cloned to date: MC1R, MC2R, MC3R, MC4R and MC5R.
  • GPCR G-protein coupled receptor
  • the melanocortin receptors participate in a variety of physiologic functions, providing a number of opportunities for therapeutic intervention in physiologic processes through alteration (i.e., a statistically significant increase or decrease) or modulation (e.g., up-regulation or down-regulation) of melanocortin receptor signalling activity.
  • the melanocortin receptor family members are regulated by natural peptide agonists such as ACTH and the melanocyte-stimulating hormones ( ⁇ -, ⁇ -, ⁇ -MSH) derived from pro-opiomelanocortin (POMC) and by peptide antagonists such as Agouti signal protein (ASP) and Agouti-related peptide (AGRP).
  • ACTH ACTH
  • ⁇ -, ⁇ -, ⁇ -MSH melanocyte-stimulating hormones
  • POMC pro-opiomelanocortin
  • ASP Agouti signal protein
  • AGPP Agouti-related peptide
  • the MC1R is widely expressed and is associated with pigmentation in melanocytes and with inflammation responses in many cells involved in the immune system.
  • the MC2R differs from the other melanocortin receptors in that it binds only ACTH but not MSH ligands. It is highly expressed in the adenal gland and controls corticosteroid synthesis.
  • the MC3R is found in the brain, but also elsewhere in the body, and appears to play a role in the regulation of energy homeostasis, and possibly sexual dysfunction.
  • the MC4R is found almost exclusively in the brain, with some reports of its presence elsewhere. It has been strongly associated with feeding control, and also implicated with sexual desire.
  • the MC5R is widely expressed in peripheral tissues, particularly in the exocrine glands, with some receptor also expressed in the brain. Given the breadth of activity associated with the melanocortin receptors it is desirable when seeking to target one of these receptors to do so selectively in order to avoid side effects associated with antagonism or agonism of another receptor in this family.
  • the MC5R has been cloned and expressed from multiple species, including humans in 1993 (though called MC2 in this paper) (Chhajlani 1993), rat in 1994 (Griffon 1994) mice in 1994 (Gantz 1994; Labbé 1994) and in 1995 (Fathi 1995), canine (Houseknecht 2003), rhesus monkey (Huang 2000), sheep (Barrett 1994), zebrafish (Ringholm 2002), goldfish (Cerdá-Reverter 2003), spiny dogfish (Klovins 2004), rainbow trout (Haitina 2004), and chicken (Ling 2004), with the MC5R gene also identified in pig (Kim 2000). Patents covering the MC5R sequence in humans (Wikberg 2002), mice (Yamada 1997), rhesus monkey (Fong 2003) and dogs (Houseknecht 2003) have been published.
  • mice lacking MC5R have reduced sebum production, as evidenced by a marked in ability to shed water from their fur, and a reduced quantity of sebum isolated from their hair. Significantly, these mice were otherwise generally healthy, with no readily visible abnormalities (appearance, behaviour, growth, muscle mass, adipose mass, reproduction, basal and stress-induced corticosterone, glucose and insulin levels) (Chen 1997). Further studies have identified reductions in pheromones, causing alterations in aggressive behaviours between mice (Caldwell 2002; Morgan 2004a; Morgan 2004b; Morgan 2006).
  • mice in which the POMC-derived peptide native ligands of MC5R have been knocked out show a similar phenotype (Yaswen 1999).
  • a synergistic effect between ⁇ -MSH and testosterone was observed in rats, with testosterone increasing sebaceous gland and cell volumes (presumably via increased proliferation), ⁇ -MSH increasing dermal lipogenesis, and the combination increasing sebum secretion (Thody 1975a; Thody 1975b).
  • human sebocytes have been shown to express MC5R, via detection of MC5R transcripts in micro-dissected sebaceous glands (Thiboutot 2000), detection of MC5R in human facial sebaceous glands by immunostaining (Hatta 2001), detection of MC5R mRNA and MC5R in human sebaceous glands, cultured human sebocytes and rat preputial cells (Thiboutot 2000) and detection of MC5R as punctate particles within sebaceous glands by staining with polyclonal antibodies, seen in differentiated but not undifferentiated sebocytes (Zhang 2006).
  • MC5R mRNA was also detected in sebaceous glands from the skin of wild-type mice, but not in skin sections of the MC5R-knockout mice (Chen 1997).
  • Treatment of human sebocytes with cholera toxin (ChT), bovine pituitary extract (BPE), ⁇ -MSH or NDP-MSH increases lipid droplet formation, squalene synthesis, and MC5R expression (Zhang 2003; Zhang 2006), While both MC1R and MC5R have been detected in sebaceous cells, treatment of primary human sebocyte cell culture with NDP-MSH or BPE caused a substantial increase in human MC5R expression compared to serum-free conditions, correlating with sebocyte differentiation.
  • a family of 1,2,4-thiadiazole derivatives with MC5R antagonist activity (138-320 nM) were found to reduce sebum formation both in human sebocyte cell cultures and when applied topically to human skin grafted onto immunodeficient mice (Eisinger 2003a-d; 2006a,b).
  • Sebaceous secretion is a common affliction. Sebaceous glands occur over most of the body, with dense concentrations of large glands on the face, scalp and upper trunk (Simpson and Cunliffe p 43.1). Sebaceous secretion is dependent in part on androgenic hormones, possibly partly mediated by 5 ⁇ -reductase processing of testosterone to 5 ⁇ -DHT (dihydrotestosterone). Sebum consists of a species-specific mixture of lipids.
  • Androgenic sex hormones appear to play a role in the development of acne, with strong correlations with sebum production (Makrantonaki 2007).
  • Two oral contraceptive pills are approved by the FDA for the treatment of acne vulgaris (Harper 2005), and these compounds appear to act by reducing androgen mediated sebum formation. Diet (Cordain 2005; Smith 2007b), stress (Zouboulis 2004) and genetic factors (Goulden 1999; Bataille 2006) also may play a role in acne, again potentially via increased sebum production.
  • acnes (Simpson and Cunliffe p 43.37, 43.46; Williams 2006). Both topical retinoids and benzoyl peroxide cause skin irritation, and retinoids can cause photosensitivity (Williams 2006).
  • Oral therapies include isotretinoin, antibiotics, hormones, and steroids. In females, antiandrogens have been shown to reduce sebum production (by approximately 40-80%, though with no placebo control group) and improve acne (Simpson and Cunliffe p 43.44; Burke 1984; Goodfellow 1984).
  • Laser and UV-based therapies are gaining acceptance, and are believed to act through heating of the sebaceous gland followed by reduction in sebum formation; with reductions in both sebum formation and acne lesions measured (Jih 2006; Bhardwaj 2005).
  • therapies available for acne only oral isotretinoin and hormonal therapies act by regulating the sebaceous gland to reduce sebum secretion (Clarke 2007).
  • oral isotretinoin 13-cis-retinoic acid, Roaccutane, Accutane
  • isotretinoin 13-cis-retinoic acid, Roaccutane, Accutane
  • Topical retinoids in contrast, have no effect on sebum production.
  • Oral isotretinoin is also anti-inflammatory, reduces comedogenesis, and reduces P. acnes infection.
  • Isotretinoin induces apoptosis and cell cycle arrest in human immortalized SEB-1 sebocyte cell culture (Nelson 2006).
  • oral isotretinoin has serious side effects; most significantly it is a teratogen and requires a registration program for use in the USA.
  • the FDA has issued a warning against online purchases of isotretinoin. Blood testing for fasting lipids and liver function is also recommended during treatment (Williams 2006). Isotretinoin has been implicated (though not substantively) with adverse psychological effects, including suicide and depression (Marqueling 2005).
  • Seborrhoea or excessive skin oil production, is often associated with severe acne.
  • Seborrheic dermatitis SD is a skin disease associated with sebum-rich areas of the scalp, face and trunk with scaly, flaky, itchy red skin affecting 3-5% of the population; dandruff represents a mild form of this dermatitis affecting 15-20% of the population.
  • Seborrhoea and SD appear more common in patients with Parkinson's disease or mood disorders (facial paralysis, supraorbital injury, poliomyelitis, syringomyelia, quadriplegia, unilateral injury to the ganglion Gasser and those with HIV/AIDS) (Plewig 1999). Studies have shown that seborrheic dermatitis is also associated with chronic alcoholic pancreatitis, hepatitis C virus and various cancers. It is also common in patients with genetic disorders, such as Down's syndrome, Hailey-Hailey disease and cardio-facio cutaneous syndrome (Gupta 2004). MC5R antagonists may be useful for treating these indications.
  • Muir-Torre syndrome consists of sebaceous gland adenomas associated with an internal adenocarcinoma (usually colon, breast, ovary or prostate). Preventing sebaceous cell differentiation may provide an effective treatment for arresting tumour growth. Oral isotretinoin has been used for this purpose (Graefe 2000). Sebaceous hyperplasia is a benign hyperplasia of the sebaceous glands, generating yellowish small papules on the skin surface, usually the face.
  • the disease is associated with excessive undifferentiated sebocyte proliferation, but not excessive sebum formation.
  • Ectopic sebaceous glands are similar yellow papules found in the mouth or on the penile shaft. Both respond to oral isotreinoin. A compound that reduced sebocyte proliferation could be an effective treatment.
  • ⁇ -MSH shows immunosuppressive effects in humans, suppressing a variety of inflammation responses, and the MC5R has been implicated in these immunomodulating activities.
  • MC5R mRNA was found to be expressed at high levels in human CD4+ T helper (Th) cells and in moderate levels in other human peripheral blood leukocytes (Andersen 2005).
  • Th human CD4+ T helper
  • MC5R was detected in the lymphoid organs (Labbé, 1994), and MC5R was found on the surface of mouse pro-B-lymphocyte cells where it appears to mediate ⁇ -MSH activation of the JAK2 signalling pathway, enhancing cellular proliferation (Buggy 1998).
  • Induction of CD25+ CD4+ regulatory T-cells by ⁇ -MSH also appears to be through MC5R (Taylor 2001).
  • Therapeutic regulation of biological signal transduction includes modulation of MC5R-mediated cellular events including, inter alia, inhibition or potentiation of interactions among MC5R-binding and activating or deactivating molecules, or of other agents that regulate MC5R activities.
  • An increased ability to so regulate MC5R may facilitate the development of methods for modulating sebum secretion or other biological processes, and for treating conditions associated with such pathways such as acne as described above.
  • the present applicants have now identified a family of 1,4-diazepan-2-ones that display MC5R antagonist activity which should be useful in treating MC5R related conditions.
  • the present invention provides compounds of formula (I):
  • Y is a group of formula —(CR 9 R 10 ) n —;
  • X is selected from the group consisting —C( ⁇ O)—, —OC( ⁇ O)—, —NHC( ⁇ O)—, —(CR 11 R 12 ) s , and —S( ⁇ O) 2 —;
  • Z is a group of formula —(CR 13 R 14 ) q —;
  • R 1 is selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl;
  • R 2 and R 3 are each independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl;
  • R 4a is selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, C( ⁇ O)R 15 , C( ⁇ O)NR 15 R 16 , C( ⁇ O)OR 15 , SO 2 R 15 , C( ⁇ O)H, —C( ⁇ NR 15 )—NR 16 R 17 , and OR 15 ,
  • R 4b is selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, C( ⁇ O)R 15 , C( ⁇ O)NR 15 R 16 , C( ⁇ O)OR 15 , or
  • R 4a and R 4b when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocyclic moiety, or
  • R 4a and R 4b when taken together with any of R 13 or R 14 forms an optionally substituted heterocyclic group
  • each R 5a and R 5b are independently selected from the group consisting of H, halogen, C 1 -C 12 alkyl, C 1 -C 12 hydroxyalkyl and C 1 -C 12 haloalkyl, or
  • R 5a and R 5b when taken together with one or more of R 6 , R 7 and R 8 and the atoms to which they are attached form a moiety selected from the group consisting of an optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl;
  • R 6 , R 7 and R 8 are each independently selected from the group consisting of H, halogen, hydroxy, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 1 -C 10 heteroalkenyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, optionally substituted C 1 -C 18 heteroaryl, optionally substituted amino, optionally substituted carboxy, C 1 -C 12 alkyloxy, and optionally substituted thio, or
  • R 6 , R 7 and R 8 when taken together with the carbon atom to which they are attached two or more of R 6 , R 7 and R 8 form a moiety selected from the group consisting of optionally substituted C 2 -C 12 alkenyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl, or
  • R 6 , R 7 and R 8 when taken together with one or more of R 5a and R 5b and the atoms to which they are attached form a moiety selected from the group consisting of an optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl;
  • each R 9 and R 10 is independently selected from the group consisting of H and optionally substituted C 1 -C 12 alkyl;
  • each R 11 and R 12 is independently selected from the group consisting of H, and optionally substituted C 1 -C 12 alkyl;
  • each R 13 and R 14 is independently selected from the group consisting of H, halogen, OH, C 1 -C 12 alkyl, C 6 -C 18 aryl, C 1 -C 12 haloalkyl, C 1 -C 12 hydroxyalkyl, C 1 -C 12 alkyloxy and C 1 -C 12 haloalkyloxy, or
  • R 13 and R 14 when taken together with the carbon to which they are attached R 13 and R 14 form an optionally substituted C 3 -C 12 cycloalkyl, or an optionally substituted C 1 -C 12 heterocycloalkyl group, or
  • R 13 and R 14 when taken together with one of R 4a , and R 4b form an optionally substituted heterocyclic group
  • each R 15 , R 16 , and R 17 is independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl, or
  • n is an integer selected from the group consisting of 1, 2, 3 and 4;
  • q is an integer selected from the group consisting of 0, 1, 2, 3, 4, and 5;
  • r is an integer selected from the group consisting of 1, 2, 3, and 4;
  • s is an integer selected from the group consisting of 1, 2, 3, and 4;
  • the invention also relates to pharmaceutical compositions including a compound of the invention with a pharmaceutically acceptable carrier, diluent or excipient.
  • the term “optionally substituted” as used throughout the specification denotes that the group may or may not be further substituted or fused (so as to form a condensed polycyclic system), with one or more non-hydrogen substituent groups.
  • the substituent groups are one or more groups independently selected from the group consisting of halogen, ⁇ O, ⁇ S, —CN, —NO 2 , —CF 3 , —OCF 3 , alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl, arylalkyl, cycloalkylalkenyl, heterocycloalkylalkenyl, aryl,
  • R a , R b , R c and R d are each independently selected from the group consisting of H, C 1 -C 12 alkyl, C 1 -C 12 haloalkyl, C 2 -C 12 alkenyl, C 2 -C 12 alkynyl, C 1 -C 10 heteroalkyl, C 3 -C 12 cycloalkyl, C 3 -C 12 cycloalkenyl, C 1 -C 12 heterocycloalkyl, C 1 -C 12 heterocycloalkenyl, C 6 -C 18 aryl, C 1 -C 18 heteroaryl, and acyl, or any two or more of R a , R b , R c and R d , when taken together with the atoms to which they are attached form a heterocyclic ring system with 3 to 12 ring atoms.
  • each optional substituent is independently selected from the group consisting of: halogen, ⁇ O, ⁇ S, —CN, —NO 2 , —CF 3 , —OCF 3 , alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, heteroalkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, hydroxy, hydroxyalkyl, alkyloxy, alkyloxyalkyl, alkyloxyaryl, alkyloxyheteroaryl, alkenyloxy, alkynyloxy, cycloalkyloxy, cycloalkenyloxy, heterocycloalkyloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, heterocycloalkenyloxy, aryloxy, heteroaryloxy, heterocycloalkenyloxy
  • Examples of particularly suitable optional substituents include F, Cl, Br, I, CH 3 , CH 2 CH 3 , OH, OCH 3 , CF 3 , OCF 3 , NO 2 , NH 2 , and CN.
  • the group may be a terminal group or a bridging group”. This is intended to signify that the use of the term is intended to encompass the situation where the group is a linker between two other portions of the molecule as well as where it is a terminal moiety.
  • alkyl alkyl
  • some publications would use the term “alkylene” for a bridging group and hence in these other publications there is a distinction between the terms “alkyl” (terminal group) and “alkylene” (bridging group). In the present application no such distinction is made and most groups may be either a bridging group or a terminal group.
  • the modifier “C 1 -C 6 ” in front of the term “alkyl” indicates that the alkyl moiety has from 1 to 6 carbon atoms.
  • the modifier “C 1 -C 18 ” in front of the term “heteroaryl” indicates that the heteroaromatic ring may have from 1 to 18 carbon atoms as part of the total number of atoms in the ring system.
  • acyl means an R—C( ⁇ O)— group in which the R group may be an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group as defined herein.
  • examples of acyl include acetyl and benzoyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the carbonyl carbon.
  • “Acylamino” means an R—C( ⁇ O)—NH— group in which the R group may be an alkyl, cycloalkyl, heterocycloalkyl; aryl or heteroaryl group as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the nitrogen atom.
  • Alkenyl as a group or part of a group denotes an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and which may be straight or branched preferably having 2-14 carbon atoms, more preferably 2-12 carbon atoms, most preferably 2-6 carbon atoms, in the normal chain.
  • the group may contain a plurality of double bonds in the normal chain and the orientation about each is independently E or Z.
  • Exemplary alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl and nonenyl.
  • the group may be a terminal group or a bridging group.
  • Alkenyloxy refers to an alkenyl-O— group in which alkenyl is as defined herein. Preferred alkenyloxy groups are C 1 -C 6 alkenyloxy groups. The group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Alkyl as a group or part of a group refers to a straight or branched aliphatic hydrocarbon group, preferably a C 1 -C 14 alkyl, more preferably a C 1 -C 10 alkyl, most preferably C 1 -C 6 unless otherwise noted.
  • suitable straight and branched C 1 -C 6 alkyl substituents include methyl, ethyl, n-propyl, 2-propyl, n-butyl, sec-butyl, t-butyl, hexyl, and the like.
  • the group may be a terminal group or a bridging group.
  • Alkylamino includes both mono-alkylamino and dialkylamino, unless specified.
  • “Mono-alkylamino” means a Alkyl-NH— group, in which alkyl is as defined herein.
  • “Dialkylamino” means a (alkyl) 2 N— group, in which each alkyl may be the same or different and are each as defined herein for alkyl.
  • the alkyl group is preferably a C 1 -C 6 alkyl group.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the nitrogen atom.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the carbonyl carbon.
  • Alkyloxy refers to an alkyl-O— group in which alkyl is as defined herein.
  • the alkyloxy is a C 1 -C 6 alkyloxy. Examples include, but are not limited to, methoxy and ethoxy.
  • the group may be a terminal group or a bridging group.
  • Alkyloxyalkyl refers to an alkyloxy-alkyl- group in which the alkyloxy and alkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Alkyloxyary refers to an alkyloxy-aryl- group in which the alkyloxy and aryl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the aryl group.
  • Alkyloxycarbonyl refers to an alkyl-O—C( ⁇ O)— group in which alkyl is as defined herein.
  • the alkyl group is preferably a C 1 -C 6 alkyl group. Examples include, but are not limited to, methoxycarbonyl and ethoxycarbonyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the carbonyl carbon.
  • Alkyloxycycloalkyl refers to an alkyloxy-cycloalkyl- group in which the alkyloxy and cycloalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the cycloalkyl group.
  • Alkyloxyheteroary refers to an alkyloxy-heteroaryl- group in which the alkyloxy and heteroaryl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heteroaryl group.
  • Alkyloxyheterocycloalkyl refers to an alkyloxy-heterocycloalkyl- group in which the alkyloxy and heterocycloalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heterocycloalkyl group.
  • Alkylsulfinyl means an alkyl-S—( ⁇ O)— group in which alkyl is as defined herein.
  • the alkyl group is preferably a C 1 -C 6 alkyl group.
  • Exemplary alkylsulfinyl groups include, but not limited to, methylsulfinyl and ethylsulfinyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • Alkylsulfonyl refers to an alkyl-S( ⁇ O) 2 — group in which alkyl is as defined above.
  • the alkyl group is preferably a C 1 -C 6 alkyl group. Examples include, but not limited to methylsulfonyl and ethylsulfonyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • Alkynyl as a group or part of a group means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched preferably having from 2-14 carbon atoms, more preferably 2-12 carbon atoms, more preferably 2-6 carbon atoms in the normal chain.
  • Exemplary structures include, but are not limited to, ethynyl and propynyl.
  • the group may be a terminal group or a bridging group.
  • Alkynyloxy refers to an alkynyl-O— group in which alkynyl is as defined herein. Preferred alkynyloxy groups are C 1 -C 6 alkynyloxy groups. The group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Aminoalkyl means an NH 2 -alkyl- group in which the alkyl group is as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Aminosulfonyl means an NH 2 —S( ⁇ O) 2 — group.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • Aryl as a group or part of a group denotes (i) an optionally substituted monocyclic, or fused polycyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) preferably having from 5 to 12 atoms per ring.
  • aryl groups include phenyl, naphthyl, and the like; (ii) an optionally substituted partially saturated bicyclic aromatic carbocyclic moiety in which a phenyl and a C 5-7 cycloalkyl or C 5-7 cycloalkenyl group are fused together to form a cyclic structure, such as tetrahydronaphthyl, indenyl or indanyl.
  • the group may be a terminal group or a bridging group.
  • an aryl group is a C 6 -C 18 aryl group.
  • Arylalkenyl means an aryl-alkenyl- group in which the aryl and alkenyl are as defined herein.
  • Exemplary arylalkenyl groups include phenylallyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkenyl group.
  • Arylalkyl means an aryl-alkyl- group in which the aryl and alkyl moieties are as defined herein. Preferred arylalkyl groups contain a C 1-5 alkyl moiety. Exemplary arylalkyl groups include benzyl, phenethyl, 1-naphthalenemethyl and 2-naphthalenemethyl. The group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Arylalkyloxy refers to an aryl-alkyl-O— group in which the alkyl and aryl are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Arylamino includes both mono-arylamino and di-arylamino unless specified.
  • Mono-arylamino means a group of formula arylNH—, in which aryl is as defined herein.
  • Di-arylamino means a group of formula (aryl) 2 N— where each aryl may be the same or different and are each as defined herein for aryl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the nitrogen atom.
  • Arylheteroalkyl means an aryl-heteroalkyl- group in which the aryl and heteroalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heteroalkyl group.
  • Aryloxy refers to an aryl-O— group in which the aryl is as defined herein.
  • the aryloxy is a C 6 -C 18 aryloxy, more preferably a C 6 -C 10 aryloxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Arylsulfonyl means an aryl-S( ⁇ O) 2 — group in which the aryl group is as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • a “bond” is a linkage between atoms in a compound or molecule.
  • the bond may be a single bond, a double bond, or a triple bond.
  • Cyclic group refers to saturated, partially unsaturated or fully unsaturated monocyclic, bicyclic or polycyclic ring system.
  • Examples of cyclic groups include cycloalkyl, cycloalkenyl and aryl.
  • Cycloalkenyl means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and preferably having from 5-10 carbon atoms per ring.
  • Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.
  • the cycloalkenyl group may be substituted by one or more substituent groups.
  • the group may be a terminal group or a bridging group.
  • Cycloalkyl refers to a saturated monocyclic or fused or spiro polycyclic, carbocycle preferably containing from 3 to 9 carbons per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, unless otherwise specified. It includes monocyclic systems such as cyclopropyl and cyclohexyl, bicyclic systems such as decalin, and polycyclic systems such as adamantane. The group may be a terminal group or a bridging group.
  • Cycloalkylalkyl means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as defined herein.
  • Exemplary monocycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Cycloalkylalkenyl means a cycloalkyl-alkenyl- group in which the cycloalkyl and alkenyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkenyl group.
  • Cycloalkylheteroalkyl means a cycloalkyl-heteroalkyl- group in which the cycloalkyl and heteroalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heteroalkyl group.
  • Cycloalkyloxy refers to a cycloalkyl-O— group in which cycloalkyl is as defined herein.
  • the cycloalkyloxy is a C 1 -C 6 cycloalkyloxy. Examples include, but are not limited to, cyclopropanoxy and cyclobutanoxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Cycloalkenyloxy refers to a cycloalkenyl-O— group in which the cycloalkenyl is as defined herein.
  • the cycloalkenyloxy is a C 1 -C 6 cycloalkenyloxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Haloalkyl refers to an alkyl group as defined herein in which one or more of the hydrogen atoms has been replaced with a halogen atom selected from the group consisting of fluorine, chlorine, bromine and iodine.
  • a haloalkyl group typically has the formula C n H (2n+1 ⁇ m) X m wherein each X is independently selected from the group consisting of F, Cl, Br and I.
  • n is typically from 1 to 10, more preferably from 1 to 6, most preferably 1 to 3.
  • m is typically 1 to 6, more preferably 1 to 3.
  • Examples of haloalkyl include fluoromethyl, difluoromethyl and trifluoromethyl.
  • Haloalkenyl refers to an alkenyl group as defined herein in which one or more of the hydrogen atoms has been replaced with a halogen atom independently selected from the group consisting of F, Cl, Br and I.
  • Haloalkynyl refers to an alkynyl group as defined herein in which one or more of the hydrogen atoms has been replaced with a halogen atom independently selected from the group consisting of F, Cl, Br and I.
  • Halogen represents chlorine, fluorine, bromine or iodine.
  • Heteroalkyl refers to a straight- or branched-chain alkyl group preferably having from 2 to 14 carbons, more preferably 2 to 10 carbons in the chain, one or more of which has been replaced by a heteroatom selected from S, O, P and N.
  • exemplary heteroalkyls include alkyl ethers, secondary and tertiary alkyl amines, amides, alkyl sulfides, and the like.
  • the group may be a terminal group or a bridging group.
  • Heteroaryl either alone or part of a group refers to groups containing an aromatic ring (preferably a 5 or 6 membered aromatic ring) having one or more heteroatoms as ring atoms in the aromatic ring with the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include nitrogen, oxygen and sulphur.
  • heteroaryl examples include thiophene, benzothiophene, benzofuran, benzimidazole, benzoxazole, benzothiazole, benzisothiazole, naphtho[2,3-b]thiophene, furan, isoindolizine, xantholene, phenoxatine, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, tetrazole, indole, isoindole, 1H-indazole, purine, quinoline, isoquinoline, phthalazine, naphthyridine, quinoxaline, cinnoline, carbazole, phenanthridine, acridine, phenazine, thiazole, isothiazole, phenothiazine, oxazole, isooxazole, furazane, pheno
  • Heteroarylalkyl means a heteroaryl-alkyl group in which the heteroaryl and alkyl moieties are as defined herein. Preferred heteroarylalkyl groups contain a lower alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl. The group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Heteroarylalkenyl means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkenyl group.
  • Heteroarylheteroalkyl means a heteroaryl-heteroalkyl- group in which the heteroaryl and heteroalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heteroalkyl group.
  • Heteroaryloxy refers to a heteroaryl-O— group in which the heteroaryl is as defined herein.
  • the heteroaryloxy is a C 1 -C 12 heteroaryloxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Heterocyclic refers to saturated, partially unsaturated or fully unsaturated monocyclic, bicyclic or polycyclic ring system containing at least one heteroatom selected from the group consisting of nitrogen, sulfur and oxygen as a ring atom.
  • heterocyclic moieties include heterocycloalkyl, heterocycloalkenyl and heteroaryl.
  • Heterocycloalkenyl refers to a heterocycloalkyl as defined herein but containing at least one double bond.
  • the group may be a terminal group or a bridging group.
  • Heterocycloalkyl refers to a saturated monocyclic, bicyclic, or polycyclic ring containing at least one heteroatom selected from nitrogen, sulfur, oxygen, preferably from 1 to 3 heteroatoms in at least one ring. Each ring is preferably from 3 to 10 membered, more preferably 4 to 7 membered.
  • heterocycloalkyl substituents include pyrrolidyl, tetrahydrofuryl, tetrahydrothiofuranyl, piperidyl, piperazyl, tetrahydropyranyl, morphilino, 1,3-diazapane, 1,4-diazapane, 1,4-oxazepane, and 1,4-oxathiapane.
  • the group may be a terminal group or a bridging group.
  • Heterocycloalkylalkyl refers to a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as defined herein.
  • exemplary heterocycloalkylalkyl groups include (2-tetrahydrofuryl)methyl, (2-tetrahydrothiofuranyl)methyl.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkyl group.
  • Heterocycloalkylalkenyl refers to a heterocycloalkyl-alkenyl- group in which the heterocycloalkyl and alkenyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the alkenyl group.
  • Heterocycloalkylheteroalkyl means a heterocycloalkyl-heteroalkyl- group in which the heterocycloalkyl and heteroalkyl moieties are as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the heteroalkyl group.
  • Heterocycloalkyloxy refers to a heterocycloalkyl-O— group in which the heterocycloalkyl is as defined herein.
  • the heterocycloalkyloxy is a C 1 -C 6 heterocycloalkyloxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Heterocycloalkenyloxy refers to a heterocycloalkenyl-O— group in which heterocycloalkenyl is as defined herein.
  • the heterocycloalkenyloxy is a C 1 -C 6 heterocycloalkenyloxy.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the oxygen atom.
  • Hydroalkyl refers to an alkyl group as defined herein in which one or more of the hydrogen atoms has been replaced with an OH group.
  • a hydroxyalkyl group typically has the formula C n H (2n+1 ⁇ x) (OH) x .
  • n is typically from 1 to 10, more preferably from 1 to 6, most preferably 1 to 3.
  • x is typically 1 to 6, more preferably 1 to 3.
  • “Lower alkyl” as a group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to 6 carbon atoms in the chain, more preferably 1 to 4 carbons such as methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
  • the group may be a terminal group or a bridging group.
  • “Sulfinyl” means an R—S( ⁇ O)— group in which the R group may be OH, alkyl cycloalkyl, heterocycloalkyl; aryl or heteroaryl group as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • “Sulfinylamino” means an R—S( ⁇ O)—NH— group in which the R group may be OH, alkyl cycloalkyl, heterocycloalkyl; aryl or heteroaryl group as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the nitrogen atom.
  • “Sulfonyl” means an R—S( ⁇ O) 2 — group in which the R group may be OH, alkyl cycloalkyl, heterocycloalkyl; aryl or heteroaryl group as defined herein.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the sulfur atom.
  • “Sulfonylamino” means an R—S( ⁇ O) 2 —NH— group.
  • the group may be a terminal group or a bridging group. If the group is a terminal group it is bonded to the remainder of the molecule through the nitrogen atom.
  • isomeric forms including diastereoisomers, enantiomers, tautomers, and geometrical isomers in “E” or “Z” configurational isomer or a mixture of E and Z isomers. It is also understood that some isomeric forms such as diastereomers, enantiomers, and geometrical isomers can be separated by physical and/or chemical methods and by those skilled in the art.
  • Some of the compounds of the disclosed embodiments may exist as single stereoisomers, racemates, and/or mixtures of enantiomers and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof, are intended to be within the scope of the subject matter described and claimed.
  • the present invention includes all pharmaceutically acceptable isotopically-labeled compounds of formula (I) wherein one or more atoms have the same atomic number as, but an atomic mass or mass number different from, the atomic mass or mass number usually found in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such 18 F, iodine, such as 123I and 125I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies.
  • the radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
  • Formula (I) is intended to cover, where applicable, solvated as well as unsolvated forms of the compounds.
  • each formula includes compounds having the indicated structure, including the hydrated as well as the non-hydrated forms.
  • pharmaceutically acceptable salts refers to salts that retain the desired biological activity of the above-identified compounds, and include pharmaceutically acceptable acid addition salts and base addition salts.
  • Suitable pharmaceutically acceptable acid addition salts of compounds of Formula (I) may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, sulfuric, and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, heterocyclic carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, fumaric, maleic, alkyl sulfonic, arylsulfonic. Additional information on pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 19th Edition, Mack Publishing Co., Easton, Pa. 1995. In the case of agents that are solids, it is understood by those skilled in the art that the inventive compounds, agents and salts may exist in different crystalline or polymorphic forms, all of which are intended to be within the scope of the present invention and specified formulae.
  • Prodrug means a compound that undergoes conversion to a compound of formula (I) within a biological system, usually by metabolic means (e.g. by hydrolysis, reduction or oxidation).
  • metabolic means e.g. by hydrolysis, reduction or oxidation.
  • an ester prodrug of a compound of formula (I) containing a hydroxyl group may be convertible by hydrolysis in vivo to the parent molecule.
  • Suitable esters of compounds of formula (I) containing a hydroxyl group are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- ⁇ -hydroxynaphthoates, gestisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.
  • ester prodrug of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.
  • ester prodrugs are those described by F. J. Leinweber, Drug Metab. Res.,18:379, 1987.
  • an acyl prodrug of a compound of formula (I) containing an amino group may be convertible by hydrolysis in vivo to the parent molecule.
  • prodrugs for these and other functional groups, including amines are described in Prodrugs: Challenges and Rewards (Parts 1 and 2); Ed V. Stella, R. Borchardt, M. Hageman, R. Oliyai, H. Maag and J Tilley; Springer, 2007)
  • Y is a group of the formula —(CR 9 R 10 ) n —. In one embodiment of the invention n is 1 and Y is —CR 9 R 10 —. In another embodiment of the invention n is 2 and Y is —CR 9 R 10 CR 9 R 10 —.
  • each R 9 and R 10 is independently selected from H and CH 3 . In one specific embodiment R 9 and R 10 are both H. Accordingly in one embodiment of the invention Y is —CH 2 —. In another embodiment of the invention Y is —CH 2 CH 2 —. In yet an even further embodiment of the invention Y is —C(CH 3 ) 2 —.
  • R 2 is H or C 1 -C 6 alkyl. In a specific embodiment R 2 is H.
  • R 3 is H or C 1 -C 6 alkyl. In a specific embodiment R 3 is H.
  • X is selected from the group consisting of —C( ⁇ O)— and —(CR 11 R 12 ) s —. In one specific embodiment X is —C( ⁇ O)—. In one embodiment of the invention where X is —(CR 11 R 12 ) s —, S is 1. In another embodiment of the invention where X is —(CR 11 R 12 ) s —, s is 2. In one form of each of these embodiments R 11 and R 12 are each independently selected from the group consisting of H and C 1 -C 6 alkyl. In a specific embodiment both R 11 and R 12 are H, and s is 1, such that X is —CH 2 —.
  • Y is CH 2 , R 2 is H, R 3 is H, and X is —C( ⁇ O)—.
  • R 1 , R 4a , R 4b , R 5a , R 5b , R 6 , R 7 , R 8 , Z and r are as defined for formula (I).
  • r is selected from the group consisting of 1, 2, 3, and 4. In one specific embodiment r is 1. In another specific embodiment r is 2. In yet a further specific embodiment r is 3. In an even further specific embodiment r is 4.
  • R 5a and R 5b are independently selected from H and C 1 -C 6 alkyl.
  • R 5a and R 5b are each independently selected from H and CH 3 .
  • R 5a and R 5b are both H.
  • at least one of R 5a and R 5b when taken together with at least one of R 6 , R 7 and R 8 and the atoms to which they are attached form an optionally substituted cycloalkyl group.
  • at least one of R 5a and R 5b when taken together with at least one of R 6 , R 7 and R 8 and the atoms to which they are attached forms a cyclohexyl group.
  • Y is CH 2 , R 2 is H, R 3 is H, R 5a and R 5b are H, X is —C( ⁇ O)—, and r is 1.
  • R 1 , R 4a , R 4b , R 6 , R 7 , R 8 , and Z are as defined for formula (I).
  • R 7 is H.
  • Y is CH 2 , R 2 is H, R 3 is H, R 5a and R 5b are H, R 7 is H, X is —C( ⁇ O)—, and r is 1.
  • R 1 , R 4a , R 4b , R 6 , R 8 , and Z are as defined for formula (I).
  • Z is a group of formula —(CR 13 R 14 ) q —.
  • R 13 and R 14 are independently selected from H and C 1 -C 6 alkyl.
  • R 13 and R 14 are each independently selected from H and CH 3 .
  • R 13 and R 14 are both H.
  • Z is a group —(CH 2 )q-.
  • at least one of R 13 and R 14 when taken together with at least one of R 4a , and R 4b and the atoms to which they are attached form an optionally substituted heterocycloalkyl group.
  • q is an integer selected from the group consisting of 0, 1, 2, 3, 4, and 5. In one specific embodiment q is 1. In another specific embodiment q is 2, in yet an even further specific embodiment q is 3, and in yet an even further specific embodiment q is 4. In circumstances where R 13 and R 14 are both H this provides compounds of formula (IVa), (IVb), (IVc) and (IVd) respectively.
  • R 1 , R 4a , R 4b , R 6 , and R 8 are as defined for formula (I).
  • R 1 , R 4a , R 4b , R 6 , and R 8 are as defined for formula (I).
  • R 1 , R 4a , R 4b , R 6 , and R 8 are as defined for formula (I).
  • R 1 , R 4a , R 4b , R 6 , and R 8 are as defined for formula (I).
  • R 6 and R 8 are each independently selected from the group consisting of H, optionally substituted C 1 -C 12 alkyl optionally substituted C 2 -C 12 alkenyl, optionally substituted C 6 -C 18 aryl and optionally substituted C 1 -C 18 heteroaryl.
  • R 6 and R 8 are each independently selected from the group consisting of optionally substituted C 1 -C 12 alkyl optionally substituted C 2 -C 12 alkenyl, optionally substituted C 6 -C 18 aryl and optionally substituted C 1 -C 18 heteroaryl.
  • R 6 and R 8 are each independently selected from the group consisting of optionally substituted C 2 -C 12 alkyl optionally substituted C 2 -C 12 alkenyl, optionally substituted C 6 -C 18 aryl and optionally substituted C 1 -C 18 heteroaryl.
  • R 6 is selected from the group consisting of ethyl, 2,2,2-trifluoroethyl, isopropyl, isopropenyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, 2-methyl-butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl-pentyl, optionally substituted phenyl and optionally substituted C 1 -C 5 heteroaryl.
  • R 6 is optionally substituted phenyl or optionally substituted C 1 -C 18 heteroaryl.
  • R 8 is selected from the group consisting of ethyl, 2,2,2-trifluoroethyl, isopropyl,isopropenyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, 2-methyl-butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl-pentyl, optionally substituted phenyl and optionally substituted C 1 -C 5 heteroaryl.
  • R 8 is methyl, ethyl, phenyl or optionally substituted C 1 -C 5 heteroaryl.
  • R 6 , R 7 and R 8 when taken together with the carbon atom to which they are attached form a moiety selected from the group consisting of optionally substituted C 2 -C 12 alkenyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl.
  • R 6 , R 7 and R 8 when taken together with the carbon atom to which they are attached form an optionally substituted C 6 -C 18 aryl group.
  • R 6 , R 7 and R 8 when taken together with the carbon atom to which they are attached form a disubstituted phenyl group.
  • the disubstituted phenyl group is a 2,4-disubstituted phen-1-yl group or a 3,5-disubstituted phen-1-yl group.
  • substituents may be present on the disubstituted phenyl group as defined above.
  • substituents include, but are not limited to, F, Br, Cl, methyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, isopropyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl-pentyl, pent-4-enyl, hexyl, heptyl, octyl, phenyl, NH 2 , cyano, phenoxy, hydroxy, methoxy, ethoxy, methylenedioxy, pyrrol-1-yl, and 3,5-dimethyl-pyrazol-1-yl.
  • the disubstituted phenyl group is a 3,5-dichlorophen-1-yl group.
  • R 4a is selected from the group consisting of H, C( ⁇ NH)NH 2 , C( ⁇ NH)N(CH 3 ) 2 , C( ⁇ NH)NHCH 3 , C( ⁇ NH)NHisopropyl, C( ⁇ O)CH 3 , C( ⁇ O)cyclohexyl, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 2 CH 3 , CH(CH 3 )CH 2 CH 3 , CH 2 CH(CH 3 ) 2 , C(CH 3 ) 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, and phenyl, or a halogenated derivative thereof.
  • R 4b is selected from the group consisting of H, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 2 CH 3 , CH(CH 3 )CH 2 CH 3 , CH 2 CH(CH 3 ) 2 , C(CH 3 ) 3 , cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, benzyl, and phenyl, or a halogenated derivative thereof.
  • R 4a and R 4b when taken together with the nitrogen atom to which they are attached form an optionally substituted cyclic group.
  • the optionally substituted cyclic group may be an optionally substituted C 2 -C 12 heterocycloalkyl group, an optionally substituted C 1 -C 12 heterocycloalkenyl group or an optionally substituted C 1 -C 18 heteroaryl group.
  • R 4a and R 4b when taken together with the nitrogen atom to which they are attached form an optionally substituted C 2 -C 12 heterocycloalkyl group.
  • R 4a and R 4b when taken together with the nitrogen atom to which they are attached form an optionally substituted heterocycloalkyl group selected from the group consisting of piperidin-1-yl, pyrrolidin-1-yl, azetidin-1-yl, morpholin-4-yl, piperazin-1-yl and azepan-1-yl.
  • NR 4a R 4b Specific examples include:
  • one of R 4a and R 4b when taken together with the nitrogen atom to which it is attached and one of R 13 and R 14 and the carbon atom to which it is attached form an optionally substituted C 2 -C 12 heterocycloalkyl group.
  • one of R 4a and R 4b when taken together with the nitrogen atom to which it is attached and one of R 13 and R 14 and the carbon atom to which it is attached form an optionally substituted C 2 -C 12 heterocycloalkyl group selected from the group consisting of piperidinyl, pyrrolidinyl, azetidinyl, morpholinyl, piperazinyl, and 1-azepanyl.
  • R 1 is selected from the group consisting of optionally substituted C 2 -C 12 alkenyl, optionally substituted C 6 -C 18 aryl and optionally substituted C 1 -C 18 heteroaryl.
  • R 1 is optionally substituted C 6 -C 18 aryl.
  • the C 6 -C 18 aryl may be a monocyclic, bicyclic or polycyclic moiety. In certain embodiments the C 6 -C 18 aryl is a monocyclic moiety. In certain embodiments the C 6 -C 18 aryl is a bicyclic moiety.
  • R 1 is an optionally substituted C 6 -C 18 aryl selected from the group consisting of optionally substituted phenyl, biphenyl, and optionally substituted naphthyl.
  • the moieties may be unsubstituted or may be substituted with one or more optional substituents.
  • a wide variety of optional substituents may be used as defined above.
  • Such optional substituents include, but are not limited to, F, Br, Cl, methyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, isopropyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl-pentyl, pent-4-enyl, hexyl, heptyl, octyl, phenyl, NH 2 , cyano, phenoxy, hydroxy, methoxy, ethoxy, pyrrol-1-yl, and 3,5-dimethyl-pyrazol-1-yl.
  • substituents may be located at any substitutable position around the aryl ring available for substitution as would be clear to a skilled addressee.
  • suitable optionally substituted phenyl compounds include, but are not limited to, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl, 4-trifluoromethyl-phenyl, 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl, 3-fluoro-phenyl, 4-fluoro-phenyl, 4-hydroxy-phenyl, 4-phenyl-phenyl, 4-methyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,5-dichloro-phenyl, 2,6-difluoro-phenyl, 2-chloro-6-
  • R 1 is optionally substituted biphenyl
  • the point of attachment of R 1 to the remainder of the molecule may be at the 2-, 3- or 4-position relative to the point of attachment of the second phenyl ring.
  • the biphenyl may be an optionally substituted biphen-2-yl, or an optionally substituted biphen-3-yl, or an optionally substituted biphen-4-yl.
  • the optionally substituted biphenyl is an optionally substituted biphen-4-yl.
  • the optionally substituted biphenyl may be substituted in any suitable position.
  • R 1 is optionally substituted naphthyl
  • the point of attachment of R 1 to the remainder of the molecule may be at the 1 or 2 positions.
  • the naphthyl may be an optionally substituted naphth-1-yl, or an optionally substituted naphth-2-yl.
  • the optionally substituted naphthyl is an optionally substituted naphth-2-yl.
  • the optionally substituted naphthyl may be substituted in any suitable position.
  • suitable optionally substituted naphth-2-yls include, but are not limited to, 6-fluoro-naphth-2-yl, 6-bromo-naphth-2-yl, 6-chloro-naphth-2-yl, 1-methoxy-naphth-2-yl, 3-methoxy-naphth-2-yl, 6-methoxy-naphth-2-yl, 1-hydroxy-naphth-2-yl, and 6-amino-naphth-2-yl.
  • R 1 is optionally substituted C 1 -C 18 heteroaryl.
  • the C 1 -C 18 heteroaryl may be a monocyclic, bicyclic or polycyclic moiety. In certain embodiments the C 1 -C 18 heteroaryl is a monocyclic moiety. In certain embodiments the C 1 -C 18 heteroaryl is a bicyclic moiety.
  • heteroaryl moieties include, but are not limited to, indol-2-yl, indol-3-yl quinolin-2-yl quinolin-3-yl, isoquinolin-3-yl, quinoxaline-2-yl, benzo[b]furan-2-yl, benzo[b]thiophen-2-yl, benzo[b]thiophen-5-yl, thiazole-4-yl, benzimidazole-5-yl, benzotriazol-5-yl, furan-2-yl, benzo[d]thiazole-6-yl, pyrazole-1-yl, pyrazole-4-yl and thiophen-2-yl. These may also be optionally substituted as discussed above.
  • R 1 is an optionally substituted C 2 -C 12 alkenyl.
  • the optionally substituted alkenyl may contain one or more double bonds with each of the double bonds being independently in the E or Z configuration.
  • the alkenyl contains a single double bond which is in the E configuration.
  • R 1 is an optionally substituted C 2 -C 12 alkenyl of the formula:
  • R 1a is selected from the group consisting of H, halogen and optionally substituted C 1 -C 12 alkyl;
  • R 1b and R 1c are each independently selected from the group consisting of H, halogen, optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, optionally substituted C 1 -C 12 heteroalkyl, optionally substituted C 3 -C 12 cycloalkyl, optionally substituted C 2 -C 12 heterocycloalkyl, optionally substituted C 6 -C 18 aryl, and optionally substituted C 1 -C 18 heteroaryl.
  • R 1a is H. In one form of this embodiment R 1b is H. This provides compounds where R 1 is of the formula:
  • R 1c is optionally substituted C 6 -C 18 aryl.
  • the C 6 -C 18 aryl may be monocyclic, bicyclic or polycyclic moiety. In certain embodiments the C 6 -C 18 aryl is a monocyclic moiety. In certain embodiments the C 6 -C 18 aryl is a bicyclic moiety.
  • R 1c is an optionally substituted C 6 -C 18 aryl selected from the group consisting of optionally substituted phenyl and optionally substituted naphthyl.
  • the moieties may be unsubstituted or may be substituted with one or more optional substituents.
  • a wide variety of optional substituents may be used as defined above.
  • Such optional substituents include, but are not limited to, F, Br, Cl, methyl, trifluoromethyl, ethyl, 2,2,2-trifluoroethyl, isopropyl, propyl, 2-ethyl-propyl, 3,3-dimethyl-propyl, butyl, isobutyl, 3,3-dimethyl-butyl, 2-ethyl-butyl, pentyl, 2-methyl-pentyl, pent-4-enyl, hexyl, heptyl, octyl, phenyl, NH 2 , cyano, phenoxy, hydroxy, methoxy, ethoxy, methylenedioxy, pyrrol-1-yl, and 3,5-dimethyl-pyrazol-1-yl.
  • substituents may be located at any substitutable position around the aryl ring available for substitution as would be clears to a skilled addressee.
  • suitable optionally substituted phenyl compounds include, but are not limited to, 2-methoxy-phenyl, 3-methoxy-phenyl, 4-methoxy-phenyl, 2-trifluoromethyl-phenyl, 3-trifluoromethyl-phenyl 4-trifluoromethyl-phenyl 2-chloro-phenyl, 3-chloro-phenyl, 4-chloro-phenyl, 4-bromo-phenyl, 2-fluoro-phenyl 3-fluoro-phenyl, 4-fluoro-phenyl, 4-hydroxy-phenyl 4-phenyl-phenyl, 4-methyl-phenyl, 2,4-dichloro-phenyl, 3,4-dichloro-phenyl, 2,5-dichloro-phenyl, 2,6-difluoro-phenyl, 2-chloro-6-fluoro
  • the compounds of the invention are antagonists of the MC5R and therefore may be used to modulate the activity of MC5R or a fragment or analogue or functional equivalent thereof by exposing MC5R or a fragment or analogue or functional equivalent thereof to a compound of the invention.
  • the compounds of the present invention may be used in the treatment of any condition in which modulation of the activity of MC5R or a fragment or analogue or functional equivalent thereof would lead to a beneficial effect on that condition.
  • the compounds of the invention may be used in methods of treating, preventing, or controlling a condition associated either directly or indirectly with the activity of MC5R or a fragment or analogue or functional equivalent thereof in a mammal wherein an MC5R modulating amount of the compound of the invention is administered to the mammal.
  • One condition associated with MC5R activity is excess sebum secretion and conditions related thereto.
  • the condition is selected from the group consisting of acne, seborrhoea, and seborrheic dermatitis.
  • the acne is selected from the group consisting of acne vulgaris, acne, acne conglobata and acne fulminans.
  • the condition is acne vulgaris.
  • downregulation of MC5R leads to a reduction of sebum secretion and can thus be used in the treatment or prophylaxis of a number of conditions in which excess sebum secretion is observed such as acne, seborrhoea and seborrheic dermatitis.
  • the compounds of the present invention may also be useful in the treatment, prevention or control of a number of conditions that relate to biological processes controlled by MC5R, such as diseases related to inflammation.
  • the compounds may also be useful for the treatment or prevention of cancers, such as Muir-Torre syndrome or other cancers of the sebaceous gland.
  • the compounds of the present invention may also find application in treatments where reduced sebum secretion is desirable such as in cosmetic treatments.
  • the compounds may thus be used in methods of reducing sebum secretion by a mammal the method comprising administering an effective amount of a compound of formula (I).
  • Administration of compounds within Formula (I) to a patient such as humans can be by topical administration, by any of the accepted modes for enteral administration such as oral or rectal, or by parenteral administration such as subcutaneous, intramuscular, intravenous and intradermal routes. Injection can be bolus or via constant or intermittent infusion.
  • the active compound is typically included in a pharmaceutically acceptable carrier or diluent and in an amount sufficient to deliver to the patient a therapeutically effective dose.
  • the compounds of the invention can be administered in any form or mode which makes the compound bioavailable.
  • One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected, the condition to be treated, the stage of the condition to be treated and other relevant circumstances. We refer the reader to Remingtons Pharmaceutical Sciences, 19 th edition, Mack Publishing Co. (1995) for further information.
  • the compounds of the present invention can be administered alone or in the form of a pharmaceutical composition in combination with a pharmaceutically acceptable carrier, diluent or excipient.
  • a pharmaceutically acceptable carrier diluent or excipient.
  • the compounds of the invention while effective themselves, are typically formulated and administered in the form of their pharmaceutically acceptable salts as these forms are typically more stable, more easily crystallised and have increased solubility.
  • compositions which are formulated depending on the desired mode of administration.
  • the present invention provides a pharmaceutical composition including a compound of Formula (I) and a pharmaceutically acceptable carrier, diluent or excipient.
  • the compositions are prepared in manners well known in the art.
  • the compounds of formula (I) may be used or administered in combination with one or more additional drug(s).
  • the compounds of the present invention may be used in combination with one or more other pharmaceutically-active compounds, such as other anti-acne treatments.
  • the other pharmaceutically active agent is selected from the group consisting of antibiotics, retinoids, anti-androgens, and steroids.
  • examples of other pharmaceutically active compounds that may be combined with a compound of formula (I) and administered in concurrent or sequential combination therewith may include, by way of non-limiting example, other anti-acne agents such as oral retinoids (e.g. isotretinoin), topical retinoids (e.g.
  • antibiotics e.g. clindamycin, erythromycin, minocycline, tetracycline, benzoyl peroxide
  • hormonal therapies e.g. drospirenone, norgestimate-ethinyl estradiol, cyproterone acetate.
  • these components can be administered in the same formulation or in separate formulations. If administered in separate formulations the compounds of the invention may be administered sequentially or simultaneously with the other drug(s).
  • a compound of the invention is typically combined with the carrier to produce a dosage form suitable for the particular patient being treated and the particular mode of administration.
  • a formulation intended for the oral administration to humans may contain from about 0.5 mg to about 5 g of the compound of the invention, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition.
  • Representative dosage forms will generally contain between from about 1 mg to about 500 mg of a compound of the invention, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
  • Compounds of the present invention may also be formulated for topical delivery in formulations such as solutions, ointments, lotions, gels, creams, microemulsions or transdermal patches.
  • these topical formulations may contain from 0.005 to 5% (wt/wt or wt/vol) of a compound of the invention.
  • compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of micro-organisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like. Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents that delay absorption such as aluminium monostearate and gelatin.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate,
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices, liposomes, and microspheres.
  • the active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • the active agent may be in the form of an ointment, cream, suspension, lotion, powder, solution, paste, gel, spray, aerosol or oil.
  • the composition may be delivered via a liposome, nanosome, rivosome, or nutri-diffuser vehicle.
  • a formulation may comprise a transdermal patch or dressing such as a bandage impregnated with an active ingredient and optionally one or more carriers or diluents.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • compositions used for topical administration typically contain a pharmaceutically acceptable carrier which may be any vehicle that is toxicologically and pharmaceutically acceptable.
  • Typical pharmaceutically acceptable carriers that can be used in compositions of the present invention include water, ethanol, acetone, isopropyl alcohol, stearyl alcohol, freons, polyvinyl pyrrolidone, propylene glycol, polyethlyene glycol, fragrances, gel-producing materials, mineral oil, stearic acid, spermaceti, sorbitan, monoleate, polysorbates, “Tweens,” sorbitol, methyl cellulose, petrolatum, a mineral oil (vaseline oil), which may be any petroleum based product; modified or unmodified vegetable oils such as peanut oil, wheatgerm oil, linseed oil, jojoba oil, apricot kernel oil, walnut oil, palm oil, pistachio oil, sesame oil, colza oil, cade oil, corn germ oil, peach kernel oil, poppy
  • compositions for topical administration may be formulated in numerous forms. However, the composition may often take the form of an aqueous or oily solution or dispersion or emulsion or a gel or a cream.
  • An emulsion may be an oil-in-water emulsion or a water-in-oil emulsion.
  • the oil phase of water-in-oil or oil-in-water emulsions may comprise for example: a) hydrocarbon oils such as paraffin or mineral oils; b) waxes such as beeswax or paraffin wax; c) natural oils such as sunflower oil, apricot kernel oil, shea butter or jojoba oil; d) silicone oils such as dimethicone, cyclomethicone or cetyldimethicone; e) fatty acid esters such as isopropyl palmitate, isopropyl myristate, dioctylmaleate, glyceryl oleate and cetostearyl isononanoate; f) fatty alcohols such as cetyl alcohol or stearyl alcohol and mixtures thereof (eg cetearyl alcohol); g) polypropylene glycol or polyethylene glycol ethers, eg PPG-14 butyl ether; or h) mixtures thereof.
  • hydrocarbon oils such as paraffin or
  • Emulsifiers used may be any emulsifiers known in the art for use in water-in-oil or oil-in-water emulsions.
  • Known cosmetically acceptable emulsifiers include: a) sesquioleates such as sorbitan sesquioleate, available commercially for example under the trade name Arlacel 83 (ICI), or polyglyceryl-2-sesquioleate; b) ethoxylated esters of derivatives of natural oils such as the polyethoxylated ester of hydrogenated castor oil available commercially for example under the trade name Arlacel 989 (ICI); c) silicone emulsifiers such as silicone polyols available commercially for example under the trade name ABIL WS08 (Th.
  • emulsifiers such as fatty acid soaps e.g. potassium stearate and fatty acid sulphates e.g. sodium cetostearyl sulphate available commercially under the trade name Dehydag (Henkel); e) ethoxylated fatty alcohols, for example the emulsifiers available commercially under the trade name Brij (ICI);] f) sorbitan esters, for example the emulsifiers available commercially under the trade name Span (ICI); g) ethoxylated sorbitan esters, for example the emulsifiers available commercially under the trade name Tween (ICI); h) ethoxylated fatty acid esters such as ethoxylated stearates, for example the emulsifiers available commercially under the trade name Myrj (ICI); i) ethoxylated mono-, di-, and tri-glycerides, for example
  • Gels for topical administration may be aqueous or non-aqueous. Aqueous gels are preferred.
  • the gel will contain a thickening agent or gelling agent in order to give sufficient viscosity to the gel.
  • a variety of thickening agents may be used according to the nature of the liquid carrier and the viscosity required and these are recited hereinafter.
  • a particularly suitable thickener is a copolymer of acryloyl dimethyl tauric acid (or a salt thereof), preferably a copolymer of that monomer with another vinylic monomer.
  • the thickening agent is a copolymer of a salt of acryloyl dimethyl tauric acid with another vinylic monomer.
  • the salt may be a salt of a Group I alkali metal, but is more preferably an ammonium salt.
  • suitable copolymer thickening agents are: i) Ammonium acryloyl dimethyl taurate I vinyl pyrrolidone copolymer, ie a copolymer of ammonium acryloyl dimethyl taurate and vinyl pyrrolidone (1-vinyl-2-pyrrolidone).
  • composition may additionally comprise other skin care active agents which are well known in the art which may be effective to aid the normal functioning of the skin.
  • One group of preferred compositions comprise hydrolysed milk protein to regulate sebum production.
  • composition may additionally comprise other components which will be well known to those skilled in the art such as emollients, humectants, emulsion stabilising salts, preservatives, chelating agents or sequestering agents (sequestrants), abrasives, anti-oxidants, stabilisers, pH adjusters, surfactants, thickeners, diluents, perfumes and colourings.
  • emollients emollients
  • humectants emulsion stabilising salts
  • preservatives chelating agents or sequestering agents (sequestrants)
  • chelating agents or sequestering agents sequestrants
  • abrasives anti-oxidants
  • stabilisers pH adjusters
  • surfactants thickeners
  • thickeners diluents, perfumes and colourings.
  • the topical formulations may desirably include a compound that enhances absorption or penetration of the active ingredient through the skin or other affected areas.
  • dermal penetration enhancers include dimethylsulfoxide and related analogues.
  • the resulting secondary amine is acylated under standard peptide coupling conditions with the protected amino acid, P 2 —NHCH(U)—CO 2 H, where U represents either the final ZNR 4a R 4b side chain, a protected final side chain, or a precursor that requires chemical modification to form the final ZNR 4a R 4b side chain.
  • Preparative scale HPLC was carried out on a Waters Delta Prep 3000 HPLC system with peak detection by UV (Waters model 486 tunable absorbance detector), using Phenomenex Luna 10 ⁇ C5 100A, 250 ⁇ 21.20 mm (20 mg scale), Phenomenex Luna 15 ⁇ C8(2) 100A, 250 ⁇ 30.00 mm (50 mg scale), or Phenomenex Luna 15 ⁇ C8(2) 100A, 250 ⁇ 50.00 mm (100 mg scale) HPLC columns.
  • the solvent system employed various gradients of 0.05% TFA in water (Solvent A) and 0.05% TFA in 90:10 acetonitrile:water (Solvent B).
  • the organic phase is then washed with 1N HCl (3 ⁇ 100 mL), H 2 O (3 ⁇ 100 mL), saturated NaHCO 3 aqueous solution (3 ⁇ 100 mL) and brine (1 ⁇ 10 mL).
  • the organic phase is then dried (MgSO 4 ) and the EtOAc removed to give the Weinreb amide (2) as a white solid or an oil.
  • the ⁇ , ⁇ -unsaturated ketone (3) may be isolated by rotary evaporation or it may be used in solution without further purification. If the intention is to use the ⁇ , ⁇ -unsaturated ketone (3) in solution the volume is reduced to 100 mL by rotary evaporation and stored for later use.
  • the DIC may be replaced with HATU (15 mmol) and DIPEA (15 mmol).
  • the reaction is stirred at room temperature overnight.
  • the DCM is removed by rotary evaporation and the residue is taken up in EtOAc (100 mL).
  • the organic layer is washed with saturated sodium bicarbonate solution (2 ⁇ 100 mL), saturated ammonium chloride solution (2 ⁇ 100 mL) and brine (2 ⁇ 100 mL).
  • the organic phase is dried and the solvent removed under reduced pressure.
  • the residue is subjected to column chromatography on silica gel using petroleum ether:EtOAc to give 5.
  • the procedure adopted for the removal of the P2 protecting group will vary depending upon the exact nature of the protecting group. As will be appreciated by a skilled addressee a large number of possible protecting groups may be used and a skilled worker in the art will readily be able to determine an appropriate procedure for the removal of any particular protecting group from procedures known in the art. Nevertheless in order to assist the reader general procedures for the removal of the more common protecting groups are provided.
  • the procedure adopted for the removal of the P1 protecting group will vary depending upon the exact nature of the protecting group. As will be appreciated by a skilled addressee a large number of possible protecting groups may be used and a skilled worker in the art will readily be able to determine an appropriate procedure for the removal of any particular protecting group from procedures known in the art. Nevertheless in order to assist the reader general procedures for the removal of the more common protecting groups are provided.
  • the amino ketone 12 (44 mg, 0.053 mmol) in DCM (2 mL) was cyclized by addition of NaBH(OAc) 3 (40mg, 0.18 mmol) in one portion at room temperature. The resulting mixture was stirred for 3 hrs, followed by addition of saturated NaHCO 3 aqueous solution (3 mL). The aqueous layer was extracted with DCM (3 ⁇ 3 mL) and the combined organic layers were dried over MgSO 4 , filtered and concentrated under reduced pressure. The residue was filtered through a short plug of silica gel eluting with DCM followed by EtOAc then EtOAc/IPA (9:1) to give the desired product 13 as a white solid. It was used in the next step without further purification. MS (ESI) 807 (M+1); HPLC t R 7.75 min.
  • the organic phase was washed with H 2 O (3 ⁇ 100 mL), saturated sodium bicarbonate solution (3 ⁇ 100 mL), H 2 O (3 ⁇ 100 mL), 1M hydrochloric acid (3 ⁇ 100 mL), brine (3 ⁇ 100 mL).
  • the organic phase was dried (MgSO 4 ) and the EtOAc removed to give the Weinreb amide 26 as a white solid (7.78 g, 64%).
  • the DCM was removed by rotary evaporation and the residue was subjected to column chromatography on silica gel using petroleum ether:EtOAc (1:1 to 0:1), providing Compound 34 as a mixture of diastereomers (0.17 g, 21%).
  • the organic phase was washed with H 2 O (3 ⁇ 100 mL), saturated sodium bicarbonate solution (3 ⁇ 50 mL), H 2 O (3 ⁇ 50 mL), 1M hydrochloric acid (3 ⁇ 50 mL), brine (3 ⁇ 50 mL).
  • the organic phase was dried (MgSO 4 ) and the EtOAc removed to give the Weinreb amide 44 as a white solid (0.43 g, 23%).
  • tert-butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate 16 (Boc-Gly Weinreb amide, 1.4 g, 6.4 mmol) in DCM (5 mL) and TFA (3 mL) were stirred at room temperature 1 hr. The solvent was removed under reduced pressure, followed by addition of DCM (20 mL) and then DIPEA until basic. The solution was cooled to 0° C. and allyl chloroformate added (1.4 mL, 13.2 mmol). The reaction was stirred at room temperature overnight. The reaction mixture was neutralised with 1 M hydrochloric acid and extracted with EtOAc. The EtOAc was removed by rotary evaporation and the residue was subjected to column chromatography on silica gel using petroleum ether:EtOAc (1:1 to 0:1), providing 44 (0.86 g, 66%).
  • reaction mixture was stirred at room temperature for 1.5 hrs, after which DCM (20 mL) was added, the organic layer washed with saturated sodium bicarbonate solution (20 mL) and H 2 O (20 mL), dried (MgSO 4 ) and evaporated to give crude 55, which was used in the next reaction without purification.
  • the alcohol (560 mg, 4.91 mmol) was converted into a mesylate by dissolving in DCM (25 mL) at 0 ° C., then adding MsCl (675 mg, 5.9 mmol) followed by Et 3 N (595 mg, 5.9 mmol). After 30 min the reaction was partitioned between DCM and 0.1 N HCl, the aqueous layer extracted with DCM (2 ⁇ ), and the organic fractions combined and washed with brine, filtered and concentrated to give 200 mg of a pale yellow oil. The crude mesylate (4.91 mmol) was dissolved in acetonitrile (20 mL) and NaN 3 (957 mg, 14.7 mmol) was added.
  • the cyclised product 58 (1.9 g) was dissolved in methanol (10 mL) with catalytic Pd/C and hydrogenated under a hydrogen atmosphere (40 psi) overnight. The reaction mixture was filtered through Celite and the methanol removed by rotary evaporation to give the amine 59 (1.86 g, 97%).
  • the Alloc/allyl protected derivative 92 (840 mg, 1.11 mmol) was dissolved in a minimum of DCM. 1,3-Dimethylbarbituric acid (346 mg, 2.22 mmol) and catalytic Pd(PPh 3 ) 4 were added, and the reaction degassed under vacuum, sealed and stirred overnight. The reaction was diluted to 50 mL with DCM, DIPEA (430 mg, 3.33 mmol) and BOP (540 mg, 1.22 mmol) were added, and the reaction stirred for 30 min.
  • the Boc derivative 99 (180 mg) in DCM (1 mL) was treated with TFA (1 mL) for 20 mL. The solvent was removed by evaporation, a solution of NaHCO 3 was added, and extracted 3 ⁇ with DCM. The dichoromethane solution was dried over MgSO 4 , filtered and evaporated to dryness. A portion (56 mg, 0.086 mmol) of the crude deprotected amine in DCM was stirred with 2-naphthoic acid (16 mg), DIPEA (60 ⁇ L) and BOP (42 mg) for 30 min. MeOH was added and the reaction stirred overnight.
  • the K 2 CO 3 was removed by filtration through a pad of Celite®, and the filtrate was washed with Pet. Spirit (800 mL ⁇ 2).
  • the MeCN phase was concentrated under reduced pressure to 400 mL, and was washed with Pet. Spirit (400 mL ⁇ 2).
  • the MeCN was further concentrated under reduced pressure to 200 mL, and was washed with Pet. Spirit (200 mL ⁇ 2). Evaporation of the final Pet. Spirit washing showed no more 1,5-dibromopentane was extracted, so the MeCN phase was concentrated under reduced pressure.
  • the crude product was purified by a combination of flash column chromatography over aminopropyl-functionalized silica gel, and/or by recrystallization from acetonitrile.
  • Compound 540 was synthesized according to the procedures in Examples 92-99, except that the Fmoc deprotection/reductive amination steps of Examples 94 and 95 were replaced by the following procedures in order to introduce the deuterium atoms.
  • NDP-MSH radiolabeled in house and purified by HPLC:
  • Representative compounds of the present invention were tested for binding in the hMC5R assay as in Example 102, with the results listed in Table 4. The compounds were tested as their trifluoroacetate or hydrochloride salts, or as their free bases.
  • Radioligand binding and cAMP assays were also conducted using membranes and cells expressing MC5R cloned from other species (mouse MC5R membranes were obtained from Euroscreen; canine, rhesus monkey, cyno monkey and guinea pig MC5 receptors were cloned and expressed from cDNA libraries and transiently transfected as described in Examples 107 and 109. Plasma membranes from the cells were tested in the radioligand assay as in Example 102.
  • Radioligand binding assays were carried out using commercial or in-house prepared hMC1R, hMC3R and hMC4R membranes and [125I] NDP-MSH, as per the hMC5R procedure in Example 102.
  • In-house plasma membranes were prepared from transfected mammalian cells (prepared as in Example 109, using plasmid DNA containing the human MC1R, MC3R or MC4R gene or other gene of interest in a plasmid vector with a mammalian origin of replication):
  • Adherent cells were washed with warm Hanks buffered saline solution (HBSS). 1 mL of cold HBSS was added to each flask and the cells were scraped off with a rubber policeman. The scraped cells were added to a 50 mL tube on ice. The plates were then rinsed twice with 5 mL cold HBSS and this was also added to the tube. The cells were centrifuged at 1000 ⁇ g for 5 mins in a bench top centrifuge and the supernatant was decanted. The remaining cell pellet was resuspended in 0.25 M sucrose. The cell suspension was centrifuged again as previously and the pellet resuspended in 5 mL of 0.25 M sucrose containing protease inhibitors.
  • HBSS Hanks buffered saline solution
  • the cells were homogenised by a 10 second pulse with an Ika disperser followed by 30 seconds on ice. The homogenisation and ice incubation was repeated three times. The mixture was then centrifuged at 1260 ⁇ g for 5 mins. The supernatant was decanted into another centrifuge tube, to which a buffer containing 50 mM Tris, pH 7.4, 12,5 mM MgCl 2 , 5 mM EGTA and protease inhibitors was added to make the volume up to 30 mL. This was centrifuged at 30,000 ⁇ g for 90 mins at 4° C. The resulting pellet was resuspended in 1 mL of the buffer above also containing 10% glycerol. Membranes were aliquoted into cryovials which were snap-frozen in a dry-ice/ethanol bath before being stored at ⁇ 80° C. until required for use.
  • the mammalian cell line human embryonic kidney cells (HEK 293), were maintained in Dulbeccos Modified Eagle's medium (DMEM) with 5% fetal bovine serum (BSA), L-glutamine, high glucose and antibiotics/antimycotics.
  • DMEM Dulbeccos Modified Eagle's medium
  • BSA fetal bovine serum
  • L-glutamine high glucose
  • antibiotics/antimycotics fetal bovine serum
  • cells were passaged using trypsin/EDTA and seeded into 75 cm 2 flasks so that they would be approximately 90% confluent the next day. The next day, the cell media was replaced with fresh antibiotic/antimycotic-containing DMEM.
  • transfection lipid Turbofectin 8.0 (Origene Technologies, MD, USA) was diluted in 1.0 mL of serum and antibiotic/antimycotic-free OptiMEM in a sterile 15 mL tube and incubated for 5 mins at room temperature. Following incubation, approximately 10-20 ⁇ g of plasmid DNA expressing the gene of interest (for example: pCMV6-XL4:Homo sapiens melanocortin 5 receptor (Origene Technologies, MD, USA)) was diluted into the transfection mix and incubated for a further 30 mins at room temperature. The DNA/lipid solution was then added drop-wise to the media covering the cells while rocking the flask gently. 24 hrs post-transfection, the cells were passaged and seeded directly into two, 75 cm 2 flasks and left to recover. 48 hrs post transfection, cells were harvested for use in assays with cell dissociation solution.
  • plasmid DNA expressing the gene of interest for example: pCMV6-
  • HEK 293 cells transiently expressing the human MC5R were suspended in stimulation buffer (Hanks buffered saline solution (HBSS), 0.1% BSA, protease inhibitors and 0.5 mM 3-Isobutyl-1-methylxanthine) at 4 ⁇ 10 6 cells/mL. 5 ⁇ l of cells, plus the compounds/peptides as described below, were added to wells of a 384-well plate as soon as possible after resuspension.
  • stimulation buffer Hors buffered saline solution (HBSS), 0.1% BSA, protease inhibitors and 0.5 mM 3-Isobutyl-1-methylxanthine
  • test compounds at varying concentrations were diluted in stimulation buffer at four times concentrate and 2.5 ⁇ l was added to wells containing cells. 2.5 ⁇ l of a four times required concentration of NDP-MSH or alpha-MSH was added to all wells containing compounds. Negative control wells contained two times concentrated NDP-MSH or alpha-MSH alone without compound.
  • test compounds at varying concentrations were diluted in stimulation buffer at two times concentrate and 5 ⁇ l was added to wells containing cells.
  • Basal level (of cAMP) control wells contained stimulation buffer only (no agonist or compounds). Known concentrations of cAMP (standards) in stimulation buffer were included on the plate, but no cells were added to these wells. The plate was then incubated for 30 mins at 37° C. with gentle shaking. After incubation, 10 ⁇ l of lysis buffer (10% Tween 20, 1 M HEPES, 0.1% BSA, protease inhibitors, ddH 2 O) was added to all wells to be measured. Detection of cAMP was then achieved using the Alphascreen cAMP kit (Perkin Elmer, USA), briefly described as follows. A dilution of 10 ⁇ l acceptor beads/mL of lysis buffer was prepared in low light conditions.
  • cAMP concentration in the cells was determined by the use of a ‘standard curve’ generated from the output of known cAMP concentrations as described below.
  • Each assay plate contained a “standard curve” of known concentrations of cAMP, in 10 fold dilutions. This is an essential part of the assay as there is high inter-plate variability.
  • the plates were read on an Envision multilabel plate reader fitted with Alphascreen technology and the raw data was imported into GraphPad Prism 4 software (GraphPad, USA) for analysis.
  • X is the logarithm of peptide/compound concentration and Y is the response.
  • Also considered in this equation are bottom plateau, top plateau of the curve and EC 50 (effective concentration, 50%)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Birds (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
US12/391,720 2008-02-29 2009-02-24 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists Active 2030-01-16 US8008291B2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
US12/391,720 US8008291B2 (en) 2008-02-29 2009-02-24 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
PT97161558T PT2257534E (pt) 2008-02-29 2009-02-27 Antagonistas 3-aminoalquil-1,4-diazepan-2-ona do recetor 5 da melanocortina
AU2009219106A AU2009219106B2 (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
MX2010009487A MX2010009487A (es) 2008-02-29 2009-02-27 Antagonistas de tipo 3-aminoalquil-1,4-diazepam-2-ona del receptor de melanocortina-5.
EP09716155.8A EP2257534B1 (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
DK09716155.8T DK2257534T3 (da) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
ES09716155.8T ES2445456T3 (es) 2008-02-29 2009-02-27 Antagonistas del receptor 5 de melanocortina 3-aminoalquil-1,4-diazepan-2-ona
CN200980112982.0A CN102007105B (zh) 2008-02-29 2009-02-27 3-氨基烷基-1,4-二氮杂环庚烷-2-酮黑皮质素-5受体拮抗剂
KR1020107021383A KR101620114B1 (ko) 2008-02-29 2009-02-27 3-아미노알킬-1,4-디아제판-2-온 멜라노코르틴-5 수용체 길항제
HK11102369.6A HK1148730B (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
PCT/AU2009/000230 WO2009105823A1 (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
JP2010547917A JP5503557B2 (ja) 2008-02-29 2009-02-27 ３−アミノアルキル−１，４−ジアゼパン−２−オンメラノコルチン−５受容体アンタゴニスト
NZ587363A NZ587363A (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
BRPI0907903-3A BRPI0907903B1 (pt) 2008-02-29 2009-02-27 Composto derivado de diazepan-2-ona e composição farmacêutica
RU2010137034/04A RU2530017C2 (ru) 2008-02-29 2009-02-27 Антагонисты 3-аминоалкил-1,4-диазепан-2-он меланокортина-5 рецептора
CA2716250A CA2716250C (en) 2008-02-29 2009-02-27 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
IL207700A IL207700A (en) 2008-02-29 2010-08-19 Antagonists of receptor 3-aminoalkyl-1,4-diazepan-2-on melanocortin-5
US13/154,144 US8343958B2 (en) 2008-02-29 2011-06-06 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3291208P 2008-02-29 2008-02-29
US3289408P 2008-02-29 2008-02-29
US12/391,720 US8008291B2 (en) 2008-02-29 2009-02-24 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/154,144 Continuation US8343958B2 (en) 2008-02-29 2011-06-06 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists

Publications (2)

Publication Number Publication Date
US20090221557A1 US20090221557A1 (en) 2009-09-03
US8008291B2 true US8008291B2 (en) 2011-08-30

Family

ID=41015440

Family Applications (1)

Application Number Title Priority Date Filing Date
US12/391,720 Active 2030-01-16 US8008291B2 (en) 2008-02-29 2009-02-24 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Country Status (16)

Country Link
US (1) US8008291B2 (https=)
EP (1) EP2257534B1 (https=)
JP (1) JP5503557B2 (https=)
KR (1) KR101620114B1 (https=)
CN (1) CN102007105B (https=)
AU (1) AU2009219106B2 (https=)
BR (1) BRPI0907903B1 (https=)
CA (1) CA2716250C (https=)
DK (1) DK2257534T3 (https=)
ES (1) ES2445456T3 (https=)
IL (1) IL207700A (https=)
MX (1) MX2010009487A (https=)
NZ (1) NZ587363A (https=)
PT (1) PT2257534E (https=)
RU (1) RU2530017C2 (https=)
WO (1) WO2009105823A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128380A1 (en) * 2009-02-27 2014-05-08 Mimetica Pty Ltd Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5503558B2 (ja) * 2008-02-29 2014-05-28 ミメチカ ピーティーワイ エルティーディー Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途
CN115381955B (zh) * 2021-05-24 2024-05-17 中国科学技术大学 黑皮质素受体mc5r的用途
KR102703324B1 (ko) * 2022-11-08 2024-09-06 국민대학교산학협력단 아미노벤즈이미다졸 유도체 및 이의 제조방법

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996022304A1 (en) 1995-01-20 1996-07-25 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US5622860A (en) 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors
WO1997015577A1 (en) 1995-10-27 1997-05-01 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO1998049186A1 (en) 1997-04-25 1998-11-05 The Regents Of The University Of California Dipeptide surrogates containing asparagine-derived tetrahydropyrimidinones
WO1999048913A1 (en) 1998-03-24 1999-09-30 The University Of Queensland Peptide turn mimetics
AU742747B2 (en) 1998-03-24 2002-01-10 Mimetica Pty Ltd Peptide turn mimetics
US6448032B1 (en) 1992-08-21 2002-09-10 Jarl Wikberg Human melanocyte stimulating hormone receptor polypeptide and DNA
WO2003040117A1 (en) 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical Corporation Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
WO2003040118A1 (en) 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical, Inc. Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US20030110518A1 (en) 2001-09-28 2003-06-12 Houseknecht Karen L. Melanocortin-5 receptor sequences and uses thereof
US6645738B1 (en) 1998-11-09 2003-11-11 Merck & Co., Inc. DNA molecules encoding the melanocortin 5 receptor protein from rhesus monkey
WO2005061467A2 (en) 2003-06-20 2005-07-07 Amgen Inc. Piperazine derivatives as bradykinin antagonists
WO2008017852A1 (en) 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152701A0 (en) * 2000-05-25 2003-06-24 Hoffmann La Roche Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US6916812B2 (en) * 2001-10-09 2005-07-12 Bristol-Myers Squibb Company Alpha-aminoamide derivatives as melanocortin agonists
AU2003216274A1 (en) * 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
US7281642B2 (en) * 2004-09-16 2007-10-16 Prime Time Toys, Ltd. Squirting toy
JP5503558B2 (ja) * 2008-02-29 2014-05-28 ミメチカ ピーティーワイ エルティーディー Ｍｃ５受容体の活性を調節する方法およびこの受容体と関連する症状の治療

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448032B1 (en) 1992-08-21 2002-09-10 Jarl Wikberg Human melanocyte stimulating hormone receptor polypeptide and DNA
US5622860A (en) 1994-02-17 1997-04-22 The Regents Of The University Of Michigan Genes encoding melanocortin receptors
WO1996022304A1 (en) 1995-01-20 1996-07-25 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
WO1997015577A1 (en) 1995-10-27 1997-05-01 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO1998049186A1 (en) 1997-04-25 1998-11-05 The Regents Of The University Of California Dipeptide surrogates containing asparagine-derived tetrahydropyrimidinones
WO1999048913A1 (en) 1998-03-24 1999-09-30 The University Of Queensland Peptide turn mimetics
AU742747B2 (en) 1998-03-24 2002-01-10 Mimetica Pty Ltd Peptide turn mimetics
US6645738B1 (en) 1998-11-09 2003-11-11 Merck & Co., Inc. DNA molecules encoding the melanocortin 5 receptor protein from rhesus monkey
US20030110518A1 (en) 2001-09-28 2003-06-12 Houseknecht Karen L. Melanocortin-5 receptor sequences and uses thereof
WO2003040118A1 (en) 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical, Inc. Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US20030162819A1 (en) 2001-11-08 2003-08-28 Magdalena Eisinger Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US20030176425A1 (en) 2001-11-08 2003-09-18 Magdalena Eisinger Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
WO2003040117A1 (en) 2001-11-08 2003-05-15 Ortho-Mcneil Pharmaceutical Corporation Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US20060030604A1 (en) 2001-11-08 2006-02-09 Magdalena Elsinger Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US20060128772A1 (en) 2001-11-08 2006-06-15 Magdalena Eisinger Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
WO2005061467A2 (en) 2003-06-20 2005-07-07 Amgen Inc. Piperazine derivatives as bradykinin antagonists
WO2008017852A1 (en) 2006-08-11 2008-02-14 Palatin Technologies, Inc. Diamine-containing, tetra- substituted piperazine compounds as melanocortin receptor modulators

Non-Patent Citations (196)

* Cited by examiner, † Cited by third party
Title
A.Ehrilich, et al.; Synthesis of cyclic peptides via efficient new coupling reagents; Tetrahedron Letters; vol. 34; Issue 30; 1993; p. 4781-4784.
A.J. Thody, et al.; Biological Sciences Possible Role of MSH in the Mammal; Nature; vol. 245; 1973; p. 207-209.
A.J. Thody, S.K. Goolamali, J.L. Burton, N.A. Plummer, S. Shuster; Plasma beta-MSH Levels in Acne Vulgaris; Brithish Journal of Dermatology; vol. 92; Issue 1; 1975; p. 43-47.
A.J. Thody, S.K. Goolamali, J.L. Burton, N.A. Plummer, S. Shuster; Plasma β-MSH Levels in Acne Vulgaris; Brithish Journal of Dermatology; vol. 92; Issue 1; 1975; p. 43-47.
Ahmed F. Abdel-Magid, Kenneth G. Carson, Bruce D. Harris, Cynthia A. Maryanoff, and Rekha D. Shah; Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures; J. Org. Chem.; 61 (11); 1996; p. 3849-3862.
Alan M W Porter; Why do we have apocrine and sebaceous glands?; J R Soc Med; 94; 2001; p. 236-237.
Albert M. Kligman; The Uses of Sebum; British Journal of Dermatology; vol. 75; Issue 8-9; 1963; p. 307-319.
Alex A. Virgilio and Jonathan A. Ellman; Simultaneous Solid-Phase Synthesis of .beta.-Turn Mimetics Incorporating Side-Chain Functionality; J. Am. Chem. Soc.; 116 (25); 1994; p. 11580-11581.
Alex A. Virgilio, et al.; Expedient Solid-Phase Synthesis of Putative β-Turn Mimetics Incorporating the i + 1, i + 2, and i + 3 Sidechains; Tetrahedron Letters; vol. 37; No. 39; 1996; p. 6961-6964.
Allaye Bocoum, et al.; Disasteroselective allylation of chiral imines. Novel application of allylcopper reagents to the enantioselective synthesis of homoallyl amines; Tetrahedron Letters; vol. 32; Issue 10; 1991; p. 1367-1370.
Amanda M. Nelson, Kathryn L. Gilliland, Zhaoyuan Cong, and Diane M. Thiboutot; 13-cis Retinoic Acid Induces Apoptosis and Cell Cycle Arrest in Human SEB-1 Sebocytes; Journal of Investigative Dermatology; vol. 126; 2006; p. 2178-2189.
André Nouvet, et al.; Synthesis of New Perhydro-(1,4)-diazepin-2-ones as Constrained Peptidomimetics; Tetrahedron Letters; 39; 1998; p. 2099-2102.
André Nouvet, et al.; Synthesis of perhydrodiazepinones as new putative peptidomimetics; Tetrahedron; 55; 1999; p. 4685-4698.
André Nouvet, Marc Binard, Frédéric Lamaty, and René Lazaro; Convenient introduction of 2-(trimethylsilyl)ethylsulfonyl (SES) amino protection on different amino acids and its use in peptidomimetic chemistry; Letters in Peptide Science, 6; 1999; p. 239-242.
Aneta Ringholm, Robert Fredriksson, Natalia Poliakova, Yi-Lan Yan, John H. Postlethwait, Dan Larhammar, and Helgi B. Schiöth; One melanocortin 4 and two melanocortin 5 receptors from zebrafish show remarkable conservation in structure and pharmacology; International Society for Neurochemistry; Journal of Neurochemistry; 82; 2002; p. 6-18.
Ann L. Marqueling, et al.; Depression and Suicidal Behavior in Acne Patients Treated with Isotretinoin: A Systematic Review; Semin Cutan Med Surg; 24; 2005; p. 92-102.
Aparecida M. Kawamoto and Martin Wills; Enantioselective synthesis of beta-hydroxy amines and aziridines using asymmetric transfer hydrogenation of alpha-amino ketones; J. Chem. Soc., Perkin Trans. 1; 2001; p. 1916-1928.
Aparecida M. Kawamoto and Martin Wills; Enantioselective synthesis of β-hydroxy amines and aziridines using asymmetric transfer hydrogenation of α-amino ketones; J. Chem. Soc., Perkin Trans. 1; 2001; p. 1916-1928.
Ari M. P. Koskinen and Henry Rapoport; Synthesis of 4-substituted pralines as conformationally constrained amino acid analogs; J. Org. Chem.; 54 (8); 1989; p. 1859-1866.
Athanassios Giannis and Thomas Kolter; Peptidomimetics for Receptor Ligands-Discovery, Development, and Medical Prespectives; Angew. Chem. Int. Engl.; 1993; 32; p. 1244-1267.
Athanassios Giannis and Thomas Kolter; Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Prespectives; Angew. Chem. Int. Engl.; 1993; 32; p. 1244-1267.
Aw Taylor and K Namba; In Vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melnocyte stimulating hormone (alpha-MSH); Immunology and Cell Biology; 79; 2001; p. 358-367.
Aw Taylor and K Namba; In Vitro induction of CD25+ CD4+ regulatory T cells by the neuropeptide alpha-melnocyte stimulating hormone (α-MSH); Immunology and Cell Biology; 79; 2001; p. 358-367.
B. Moon Kim, Sung Jin Bae, Soon Mog So, Hyun Tae Yoo, Sun Ki Chang, Jung Hwan Lee, and JaeSung Kang; Synthesis of a Chiral Aziridine Derivative as a Versatile Intermediate for HIV Protease Inhibitors; Organic Letters 2001; vol. 3, No. 15; p. 2349-2351.
Benjamin Gardner, et al.; Conformationally Constrained Nonpeptide β-turn Mimetics of Enkephalin; Tetrahedron; vol. 49; No. 17; 1993; p. 3433-3448.
Burke, BM and Cunliffe, WJ; Oral spironolactone therapy for female patients with acne; British Journal of Dermatology; vol. 112; 1984; p. 124-126.
C Williams and A.M. Layton; Treatment of Acne: An Update; Expert Review of Dermatology; vol. 1; Issue 3; 2006; p. 429-438.
C.M. Wilmot, et al.; β-Turns and their distortions: a proposed new nomenclature; Protein Engineering; vol. 3; No. 6; 1990; p. 479-493.
Caurnel Morgan and Roger Cone; Melanocortin-5 Receptor Deficiency in Mice Blocks a Novel Pathway Influencing Pheromone-Induced Aggression; Behavior Genetics; vol. 36; No. 2; Mar. 2006; p. 291-300.
Caurnel Morgan, Ruth E. Thomas, and Roger D. Cone; Melanocortin-5 receptor deficiency promotes defensive behavior in male mice; Hormones and Behavior; 45; 2004; p. 58-63.
Caurnel Morgan, Ruth E. Thomas, Weidong Ma, Milos V. Novotny, and Roger D. Cone; Melanocortin-5 Receptor Deficiency Reduces a Pheromonal Signal for Aggression in Male Mice; Chem. Senses; 29; 2002; p. 111-115.
Cotterill, Cunliffe, Williamson; Severity of Acne and Sebum Excretion Rate; British Journal of Dermatology; vol. 85; 1971; p. 93-94.
David K. Chalmers and Garland R. Marshall; Pro-D-NMe-Amino Acid and D-Pro-NMe-Amino Acid: Simple, Efficient Reverse-Turn Constraints; J. Am. Chem. Soc.; 117 (22); 1995; p. 5927-5937.
David L. Hughes; The Mitsunobu Reaction; Organic Reactions; vol. 42; 1992; p. 335-656.
Derek H. R. Barton; The Invention of Chemical Reactions; Aldrichimica Acta; vol. 23; No. 1; 1990.
Diane Thiboutot, Aruntha Sivarajah, Kathryn Gilliland, Zhaoyuan Cong, and Gary Clawson; The Melanocortin 5 Receptor is Expressed in Human Sebaceous Glands and Rat Preputial Cells; The Journal of Investigative Dermatology; 2000; 115; p. 614.
E. Makrantonaki and C.C. Zouboulis; Testosterone metabolism to 5alpha-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes; British Journal of Dermatology; 156; 2007; p. 428-432.
E. Makrantonaki and C.C. Zouboulis; Testosterone metabolism to 5α-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes; British Journal of Dermatology; 156; 2007; p. 428-432.
E. Mallon, J.N. Newton, A. Klassen, S.L. Stewart-Brown, T.J. Ryan, and A.Y. Finlay; The quality of life in acne: a comparison with general medical conditions using generic questionnaires; British Journal of Dermatology; 140; 1999; p. 672-676.
E.J. Milner-White, et al.; One Type of Gamma-turn, Rather Than the Other Gives Rise to Chain-reversal in Proteins; J. Mol. Biol.; 204; 1988; p. 777-782.
Eric M. Gordon, Ronald W. Barrett, William J. Dower, Stephen P.A. Fodor, and Mark A. Gallop; Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions; J. Med. Chem.; 37 (10); 1994; p. 1385-1401.
F. Javier Sardina and Henry Rapoport; Enantiospecific Synthesis of Heterocycles from alpha-Amino Acids; Chem. Rev.; 1996; 96 (6); p. 1825-1872.
F. Javier Sardina and Henry Rapoport; Enantiospecific Synthesis of Heterocycles from α-Amino Acids; Chem. Rev.; 1996; 96 (6); p. 1825-1872.
F. William Danby; Why we have sebaceous glands; J Am Acad Dermatol; 52; 2005; p. 1071-2.
Fumio Ide, et al.; Benign lymphoepithelial lesion of the parotid gland with sebaceous differentiation; Oral Pathol Oral Radiol Endod; 97; 1999; p. 721-4.
G. Hölzemann; Peptide Conformation Mimetics (Part 1); Kontake (Darmstadt); 1991; 1.
G. Hölzemann; Peptide Conformation Mimetics (Part 2); Kontake (Darmstadt); 1991; 2.
G. Valle, et al.; Crystal-state structural analysis of two γ-lactam-restricted analogs of Pro-Leu-Gly-NH2; Int. J. Peptide Protein res.; 33; 1989; p. 181-190.
G. Valle, M. Crisma, C. Toniolo, K.-L. Yu, R.L. Johnson; Crystal-state structural analysis of two gamma-lactam-restricted analogs of Pro-Leu-Gly-NH2; International Journal of Peptide and Protein Research; vol. 33; Issue 3; 1989; Online 2009; p. 181-190.
G. Valle, M. Crisma, C. Toniolo, K.-L. Yu, R.L. Johnson; Crystal-state structural analysis of two γ-lactam-restricted analogs of Pro-Leu-Gly-NH2; International Journal of Peptide and Protein Research; vol. 33; Issue 3; 1989; Online 2009; p. 181-190.
G.E. Piérard, C. Piérard-Franchimont, T. Lê; Seborrhoea in Acne-Prone and Acne-Free Patients; Dermatologica; 175; 1987; p. 5-9.
G.N. Andersen; Quantitative Measurement of the Levels of Melanocortin Receptor Subtype 1, 2, 3 and 5 and Pro-Opio-Melanocortin Peptide Gene Expression in Subsets of Human Peripheral Blood Leucocytes; Scandinavian Journal of Immunology; 2005; 61; p. 279-284.
Gary L. Olson, David R. Bolin, Mary Pat Bonner, Michael Bos, Charles M. Cook, David C. Fry, Bradford J. Graves, Marcos Hatada, David E. Hill; Concepts and progress in the development of peptide mimetics; J. Med. Chem.; 36 (21); 1993; p. 3039-3049.
Gary W. Kramer, et al.; XIX*. The Preparation and Some Unusual Chemistry of B-Allyl Derivatives of 9-Borabicyclo[3.3.1]Nonane; Journal of Organometallic Chemistry; 132; 1977; p. 9-27.
Gary W. Kramer, et al.; XVII. Reaction of Oranometallics with Dialkylborane Derivatives: The Synthesis of Mixed Organoboranes not Available Via Hydroboration; Journal of Organometallic Chemistry; 73; 1974; p. 1-16.
George D. Rose, et al.; Turns in Peptides and Proteins; Advances in Protein Chemistry; vol. 37; 1985; p. 1-97.
Goldstein, Socha-Szott, Thomsen, Pochi, Shalita, Strauss; Comparative Effect of Isotretinoin and Etritnate on Acne and Sebaceous Gland Secretion; J. Am. Acad. Dermatol.; vol. 6; Issue 4; 1982; p. 760-765.
Goodfellow, Alaghband-Zadeh, Carter, Cream, Holland, Scully, Wise; Oral spironolactone improves acne vulgaris and reduces sebum excretion; British Journal of Dermatology; vol. 111; 1984; p. 209-214.
Gordon W. Gribble, et al.; Sodium Borohydride in Carboxylic Acid Media. A Review of the Synthetic Utility of Acyloxyborohydrides; Organic Preparations and Procecures Int.; 17; (4-5); 1985; p. 317-384.
Guibourdenche, et al.; Aminoacides, Peptides et Chimie Heterocyclique; Bull. Soc. Chim. Belg.; 1994; vol. 103; p. 1-8.
Harris HH, Downing DT, Stewart ME, Strauss JS; Sustainable rates of sebum secretion in acne patients and matched normal control subjects; J. Am. Acad. Dermatol.; vol. 8; Issue 2; 1983; p. 200-203.
Heather K. Caldwell and John J. Lepri; Disruption of the Fifth Melanocortin Receptor Alters the Urinary Excretion of Aggression-modifying Pheromones in Male House Mice; Chem. Senses; 27; 2002; p. 91-94.
Herbert C. Brown and Krishna S. Bhat; Enantiomeric Z- and E-crotyldiisopinocampheylboranes. Synthesis in high optical purity of all four possible stereoisomers of .beta.-methylhomoallyl alcohols; J. Am Chem. Soc.; 108 (2); 1986; p. 293-294.
Herbert C. Brown and Prabhakar K. Jadhav; Asymmetric carbon-carbon bond formation via .beta.-allyldiisopinocampheylborane. Simple synthesis of secondary homoallylic alcohols with excellent enantiomeric purities; J. Am. Chem. Soc.; 105 (7); 1983; p. 2092-2093.
Herbert C. Brown and Prabhaker K. Jadhav; B-Allyldiisocaranylborane: a new, remarkable enantioselective allylborating agent for prochiral aldehydes. Synthesis of homoallylic alcohols approaching 100% enantiomeric purities; J. Org. Chem.; 49 (21); 1984; p. 4089-4091.
Herbert C. Brown, et al.; Forty years of hydride reductions; Tetrahedron; vol. 35; Issue 5; 1979; p. 567-607.
Herbert C. Brown, et al.; Highly Selective Conversion or Terminal Olefins into Aldehydes; Synthesis; 1980; p. 151-153.
Herbert C. Brown, et al.; Organoboranes for synthesis. 4 : Oxidation of organoboranes with pyridinium chlorochromate. A direct synthesis of aldehydes from terminal alkenes via hydroboration; Tetrahedron; vol. 42; Issue 20; 1986; p. 5515-5522.
Herbert C. Brown, Ramnarayan S. Randad, Krishna S. Bhat, Marek Zaidlewicz, and Uday S. Racheria; Chiral synthesis via organoboranes. 24. B-allylbis(2-isocaranyl)borane as a superior reagent for the asymmetric allylboration of aldehydes; J. Am. Chem. Soc.; 112 (6); 1990; p. 2389-2392.
Herbert Meier and Klaus-Peter Zeller; The Wolff Rearrangement of alpha-Diazo Carbonyl Compounds; Angew. Chem. Internat. Edit.; vol. 14; No. 1; 1975.
Herbert Meier and Klaus-Peter Zeller; The Wolff Rearrangement of α-Diazo Carbonyl Compounds; Angew. Chem. Internat. Edit.; vol. 14; No. 1; 1975.
Hiroshi Nakanishi, et al.; Design of Peptidomimetics; Practice of Medicinal Chemistry; 27; 1996; p. 571-590.
Holger Wenschuh, Michael Beyermann, Eberhard Krause, Michael Brudel, Ruediger Winter, Michael Schuemann, Louis A. Carpino, and Michael Bienert; Fmoc Amino Acid Flourides: Convenient Reagents for the Solid-PhaseAssembly of Peptides Incorporating Sterically Hindered Residues; J. Org. Chem.; 59 (12); 1994; p. 3275-3280.
Horacio F. Olivo, Michael S. Hemenway, Amy C. Hartwig, and Raymond Chan; New Preparation of Activated 2-Vinylaziridines from 1,4-Aminoalcohols; Synlett; Mar. 1998; p. 247-248.
Horst Kessler, et al.; Design of superactive and selective integrin receptor antagonists containing the RGD sequence; Letters in Peptide Science; 2; 1995; p. 155-160.
Huang RR, Singh G, Van Der Ploeg LH, Fong TM; Species-Dependent Pharmacological Properties of the Melanocortin-5 Receptor; J. Receptor Sig. Trans. Res.; vol. 20; Issue 1; 2000; p. 47-59.
I Follador, L Campelo; Impact of Acne on Quality of Life; Expert Review of Dermatology; vol. 1; Issue 1; 2006; p. 181-184.
I.D. Kuntz; Protein folding; J. Am. Chem. Soc.; 94 (11); 1972; p. 4009-4012.
Ibon Alkorta, Maria Luisa Suarez, Rosario Herranz, Rosario González-Muñiz and M. Teresa García-López; Similarity Study on Peptide gamma-turn Conformation Mimetics; J. Mol. Model.; 2; 1996; p. 16-25.
Ibon Alkorta, Maria Luisa Suarez, Rosario Herranz, Rosario González-Muñiz and M. Teresa García-López; Similarity Study on Peptide γ—turn Conformation Mimetics; J. Mol. Model.; 2; 1996; p. 16-25.
Ira Gantz, Yoshimasa Shimoto, Yoshitaka Konda, Hiroto Miwa, Chris J. Dickinson, and Tadataka Yamada; Molecular Cloning, Expression, and Characterization of a Fifth Melanocortin Receptor; Biochemical and Biophysical Research Communications; Vo. 200, No. 3; 1994; p. 1214-1220.
James F. Callahan, John W. Bean, Joelle L. Burgess, Drake S. Eggleston, Shing Mei Hwang, Kenneth D. Kopple, Paul F. Koster, Andrew Nichols, Catherine E. Peishoff; Design and synthesis of a C7 mimetic for the predicted .gamma.-turn conformation found in several constrained RGD antagonists; J. Med. Chem.; 35 (21); 1992; p. 3970-3972.
James R. Henry, et al.; Mitsunobu reactions of n-alkyl and n-acyl sulfonamides—an efficient route to protected amines; Tetrahedron Letters; vol. 30; Issue 42; 1989; p. 5709-5712.
Jane S. Richardson; The Anatomy and Taxonomy of Protein Structure; Advances in Protein Chemistry; vol. 34; 1985; 167-330.
Janis Klovins, Tatjana Haitina, Aneta Ringholm, Maja Löwgren, Davids Fridmanis, Maija Slaidina, Susanne Stier, and Helgi B. Schiöth; Cloning of two melanocortin (MC) receptors in spiny dogfish MC3 receptor in cartilaginous fish shows high affinity to ACTH-derived peptides while it has lower preference to gamma-MSH; Eur. J. Biochem.; 271; 2004; p. 4320-4331.
Janis Klovins, Tatjana Haitina, Aneta Ringholm, Maja Löwgren, Davids Fridmanis, Maija Slaidina, Susanne Stier, and Helgi B. Schiöth; Cloning of two melanocortin (MC) receptors in spiny dogfish MC3 receptor in cartilaginous fish shows high affinity to ACTH-derived peptides while it has lower preference to γ-MSH; Eur. J. Biochem.; 271; 2004; p. 4320-4331.
Janusz Jurczak and Adam Golebiowski; Optically active N-protected .alpha.-amino aldehydes in organic synthesis; Chem. Rev.; 1989; 89 (1); p. 149-164.
Japanese Office Action Summary; Mailing Date Feb. 17, 2009.
Jarl ES Wikberg; Melanocortin receptors: new opportunities in drug discovery; Exp. Opin. Ther. Pat. (2001); 11; 61; Ashley Publications Ltd. ISSN; 2001; p. 1354-3776.
Jean Pierre Wolf and Henry Rapoport; Conformationally constrained peptides. Chirospecific synthesis of 4-alkyl-substituted .gamma.-lactam-bridged dipeptides from L-aspartic acid; J. Org. Chem.; 54 (13); 1989; p. 3164-3173.
Jean-Alain Fehrentz, et al.; An Efficient Synthesis of Optically Active α-(t-Butoxycarbonylamino)-aldehydes from α-Amino Acids; Synthesis; 1983; p. 676-678.
Jeffery W. Kelly, Nita L. Anderson, and Slayton A. Evans Jr.; Cyclodehydration of N- and C-substituted .beta.-amino alcohols to the corresponding aziridines with diethoxytriphenylphosphorane; J. Org. Chem.; 51 (1); 1986; p. 95-97.
Jeong, S.K., et al.; Intracellular calcium mobilization is medicated by the melanocortin receptors in SZ95 sebocytes; J. Investigative Dermatol; 2007; 127; p. S72; Abstract 431; Society for Investigative Dermatology; May 2007; Los Angeles, CA.
John A. Soderquist and M. Ramin Najafi; Selective oxidation of organoboranes with anhydrous trimethylamine N-oxide; J. Org. Chem.; 51 (8); 1986; p. 1330-1336.
John L. Krstenansky, Robert L. Baranowski, and Bruce L. Currie; A New Approach to Conformationally Restricted Peptide Analogs: Rigid beta-Bends. 1. Enkephalin as an Example; Biochemical and Biophysical Research Communications; vol. 109, No. 4; 1982; p. 1368-1374.
John L. Krstenansky, Robert L. Baranowski, and Bruce L. Currie; A New Approach to Conformationally Restricted Peptide Analogs: Rigid β-Bends. 1. Enkephalin as an Example; Biochemical and Biophysical Research Communications; vol. 109, No. 4; 1982; p. 1368-1374.
John T. Carlock, et al.; A mild quamtitative method for the synthesis of a variety of heterocyclic systems; Tetrahedron Letters; vol. 19; Issue 52; 1978; p. 5153-5156.
Jonathan B. Ball and Paul F. Alewood; Conformational Constraints: Nnpeptide beta-Turn Mimics; Journal of Molecular Recognition; vol. 3; No. 2; 1990.
Jonathan B. Ball and Paul F. Alewood; Conformational Constraints: Nnpeptide β-Turn Mimics; Journal of Molecular Recognition; vol. 3; No. 2; 1990.
Jonathan B. Ball, et al.; β-Turn Topography; Tetrahedron; vol. 49; No. 17; 1993; p. 3467-3478.
Jones, King, Miller, Cunliffe; A dose response study of 13-cis-retinoic acid in acne vularis; British Journal of Dermatology; vol. 108; 1983; p. 333-343.
Jörg S. Früchtel and Günther Jung; Organic Chemistry on Solid Supports; Angew. Chem. Int. Ed. Engl.; 1996; 35; p. 17-42.
José Miguel Cerdá-Reverter, Maria Kristina Ling, Helgi Birgir Schiöth, and Richard Ector Peter; Molecular cloning, characterization and brain mapping of the melanocortin 5 receptor in the goldfish; International Society for Neurochemistry; J. Neurochem.; 10.1046/j.; 2003; p. 1471-4159.
Joseph J. Buggy; Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway; Biochem, J.; 1998; 331; p. 211-216.
Joseph J. Buggy; Binding of α-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway; Biochem, J.; 1998; 331; p. 211-216.
Jranz-Josef Leinweber; Possible Physiological Roles of Carboxylic Ester Hydrolases; Drug Metabolism Reviews; 1987; 18:4; p. 379-439.
Julie C. Harper; Hormonal Therapy for Acne Using Oral Contraceptive Pills; Semin Cutan Med Surg; 24; 2005; p. 103-106.
Jürg R. Pfister; A One-Pot Synthesis of Aziridines from 2-Aminoethanols1; Synthesis; 1984; p. 969-970.
K. Mourelatos, E.A. Eady, W.J. Cunliffe, S.M. Clark, and J.H. Cove; Temporal changes in sebum excretion and propionibacterial colonization in preadolescent children with and without acne; British Journal of Dermatology; 156; 2007; p. 22-31.
Kenneth A. Newlander, James F. Callahan, Michael L. Moore, Thaddeus A. Tomaszek Jr., and William F. Huffman; A novel constrained reduced-amide inhibitor of HIV-1 protease derived from the sequential incorporation of .gamma.-turn mimetics into a model substrate; 36 (16); 1993; p. 2321-2331.
Kim, K.S.; Marklund, S.; Rothschild, M.F.; The porcine melanocortin-5-receptor (MC5R) gene: polymorphisms, linkage and physical mapping; Animal Genetics; 2000; 31; p. 230-231.
King, Jones, Daltrey, Cunliffe; A double-blind study of the effects of 13-cis-reetinoic acid on acne, sebum secretion rate and microbial population; British Journal of Dermatology; vol. 107; Issue 5; 1982; p. 583-590.
Li Zhang, et al.; Melanocortin-5 receptor: A marker of human sebocyte differentiation; Peptides; 27; 2006; p. 413-420.
Li Zhang, Mike Anthonavage, Qiuling Huang, Wen-Hwai Li, and Magdalena Eisinger; Proopiomelanocortin Peptides and Sebogenesis; Ann. N.Y. Acad. Sci.; 994; 2003; p. 154-161.
Linda Yaswen, et al.; Obesity in the mouse model of pro-opiomelanocortin deficiency response to peripheral melanocortin; Nature Medicine; vol. 5; No. 9; 1999; p. 1066-1070.
Loren Cordian; Implications for the Role of Diet in Acne; Semin Cutan Med Surg; 24; 2005; p. 84-91.
Lorin A. Thompson and Jonathan A. Ellman; Synthesis and Applications of Small Molecule Libraries; Chem. Rev.; 1996; 96 (1); p. 555-600.
Louis A. Carpino, Dean Sadat-Aalaee, Hann Guang Chao, and Robert H. DeSelms; [(9-Fluorenylmethyl)oxy]carbonyl (FMOC) amino acid fluorides. Convienient new peptide coupling reagents applicable to the FMOC/tert-butyl strategy for solution and solid-phase syntheses; J. Am. Chem. Soc.; 112 (26); 1990; p. 9651-9652.
Louis A. Carpino, et al.; Racemization studies during solid-phase peptide synthesis using azabenzotriazole-based coupling reagents; Tetrahedron Letters; vol. 35; Issue 15; 1994; p. 2279-2282.
M. Rajan Mariappan, Oluwole Fadare, Dhanpat Jain; Sebaceous Differentiation in Salivary Glands; Arch Pathol Lab Med; vol. 128; Feb. 2004.
Maher Qabar, et al.; Pharmaceutical applications of peptidomimetics; Letters in Peptide Science; 3; 1996; p. 25-30.
Marco Frigerio, et al.; A mild oxidizing reagents for alcohols and 1,2-diols: o-iodoxybenzoic acid (IBX) in DMSO; Tetrahedron Letters; vol. 35; Issue 43; 1994; p. 8019-8022.
Maria K. Ling, Eri Hotta, Zuzana Kilianova, Tatjana Haitina, Aneta Ringholm, Lisa Johansson, Nicole Gallo-Payet, Sakae Takeuchi & Helgi B. Schiöth; The melanocortin receptor subtypes in chicken have high preference to ACTH-derived peptides; British Journal of Pharmacology; 143; 2004; p. 626-637.
Mark A. Gallop, Ronald W. Barrett, William J. Dower, Stephen P.A. Fodor, and Eric M. Gordon; Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries; J. Med. Chem.; 37 (9); 1994; p. 1233-1251.
Markus Böhm, Thomas A. Luger, Desmond J. Tobin, and José Carlos García-Borrón; Melanocortin Receptor Ligands: New Horizons for Skin Biology and Clinical Dermatology; Journal of Investigative Dermatology; vol. 126; 2006; p. 1966-1975.
Martin J. Humphries, Paul M. Doyle and C. John Harris; Integrin antagonists as modulators of adhesion; Exp. Opin. Ther. Patents; 4(3); 1994; p. 227-235.
Michael C. Hillier, James P. Davidson, and Stephen F. Martin; Cyclopropane-Derived Peptidomimetics. Design, Synthesis, and Evaluation of Novel Ras Farnesyltransferase Inhibitors; J. Org. Chem.; 66; 2001; p. 1657-1671.
Michael Kahn; Peptide Secondary Structure Mimetics: Recent Advances and Future Challenges; Synlett; 1993; 821-826.
Ming H. Jih, Paul M. Friedman, Leonard H. Goldbert, Michele Robles, Adrienne S. Glaich, and Arash Kimyai-Asadi; The 1450-nm diode laser for facial inflammatory acne vulgaris: Dose-response and 12-month follow-up study; the American Academy of Dermatology, Inc.; J. Acad. Dermatol.; vol. 55; No. 1; p. 80-87; 2006.
Miyuki Anzai, Reiko Yanada, Nobutaka Fujii, Hiroaki Ohno, Toshiro Ibuka, and Yoshiji Takemoto; Asymmetric synthesis of beta2,3-amino acids by Inl-Pd(0)-promoted metalation and addition of chiral 2-vinylaziridines; tetrahedron 58 (2002); p. 5231-5239.
Miyuki Anzai, Reiko Yanada, Nobutaka Fujii, Hiroaki Ohno, Toshiro Ibuka, and Yoshiji Takemoto; Asymmetric synthesis of β2,3-amino acids by Inl-Pd(0)-promoted metalation and addition of chiral 2-vinylaziridines; tetrahedron 58 (2002); p. 5231-5239.
Naohito Hatta, Craig Dixon, Amanda J. Ray, Sion R. Phillips, William J. Cunliffe, Mike Dale, Carol Todd, Simon Meggit, Mark A. Birch-Machin, and Jonathan L. Rees; Expression, Candidate Gene, and Population Studies of the Melanocortin 5 Receptor; The Journal of Investigative Dermatology; 2001; 116; p. 564.
Nathalie Galéotti, et al.; Formation of Oxazolines and Thiazolies in Peptides by the Mitsunobu Reaction; Tetrahedron Letters; vol. 33; No. 20; 1992; p. 2807-2810.
Nathalie Griffon, Virginie Mignon, Patricia Facchinetti, Jorge Diaz, Jean-Charles Schwartz, and Pierre Sokoloff; Molecular Cloning and Characterization of the Rat Fifth Melanocortin Receptor; Biochemical and Biophysical Research Communications; Vo. 200, No. 2; 1994; p. 1007-1014.
Olivier Labbé, Frank Desarnaud, Dominique Eggerickx, Gilbert Vassart, and Marc Parmentier; Molecular Cloning of a Mouse Melanocortin 5 Receptor Gene Widely Expressed in Peripheral Tissues; Biochemistry; 1994; 33; p. 4543-4549.
P. Barrett, A. MacDonald, R. Helliwell, G. Davidson, and P. Morgan; Cloning and expression of a new member of the melanocyte-stimulating hormone receptor family; Journal of Molecular Endocrinology; (1994); 12; p. 203-213 (Abstract).
Patrice Ribière, Valérie Declerck, Jean Martinez, and Frédéric Lamaty; 2-(Trimethylsilyl)ethanesulfonyl (or SES) Group in Amine Protection and Activation; Chem. Ref.; 106 2006; p. 2249-2269.
PCT Search Report; PCT/AU2009/000231; Mar. 11, 2009.
PCT Search Report; PCT/AU2009/00230; Mar. 11, 2009.
Peter N. Lewis, Frank A. Momany, and Harold A. Scheraga; Chain Reversals in Proteins; Biochemica et Biophysica Acta.; 303; 1973; p. 211-229.
Peter Wipf and Paul C. Fritch; SN2′—Reactions of Peptide Aziridines. A Cuprate-Based Approach to (E)-Alkene Isosteres; J. Org. Chem.; 1994; 59; p. 4875-4886.
Peter Wipf and Paul C. Fritch; SN2'-Reactions of Peptide Aziridines. A Cuprate-Based Approach to (E)-Alkene Isosteres; J. Org. Chem.; 1994; 59; p. 4875-4886.
Peter Wipf, et al.; An Investigation of the Mitsunobu Reaction in the Preparation of Peptide Oxazolines, Thiazolines, and Aziridines; Tetrahedron Letters; vol. 33; No. 42; 1992; p. 6267-6270.
Phan, J., et al.; P. acnes induced inflammation via TLR2 and upregulates antimicrobial activity in sebocytes; J. Investigative Dermatol; 2007; 127; p. s126; Abstract 754; Society for Investigative Dermatol; May 2007; Los Angeles, CA.
Philip L. Robinson, Carey N. Barry, S. Woody Bass, Susan E. Jarvis, and Slayton A. Evans Jr.; Regioselective cyclodehydration of chiral diols with diethoxytriphenylphosphrane, tripheynlpospine-tetrachloromethane-potassium carbonate, and triphenylphosphine-diethyl azodicarboxylate reagents. A comparative study; J. Org. Chem.; 48(26); 1983; p. 5396-5398.
Plewig G. and Jansen T.; Chapter 22 Seborrheic dermatitis; In: Dermatology in General Medicine, Freedberg IM, EisenAZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB (Eds) 5th ed. McGraw Hill, New York; 1999; p. 1482-1489.
Pochi, Strauss; Sebum production, casual sebum levels, titratable acidity of sebum, and urinary fractional 17-ketosteroid excretion in males with acne; The Journal of Investigative Dermatology; vol. 43; 1964; p. 383-388.
Rahul Ray, et al.; Osmium tetroxide catalyzed hydroxylation of hindered; Tetrahedron Letters vol. 21; Issue 5; 1980; p. 449-450.
Ralph Hirschmann, .C. Nicolaou, Sharrie Pietranico, Ellen M. Leahy, Joseph Salvino, Byron Arison, Maria A. Cichy, P. Grant Spoors, William C. Shakespeare; De novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing .beta.-D-glucose as a novel scaffolding; J. Am. Chem. Soc.; 115 (26); 1993; p. 12550-12568.
Ralph Hirschmann, et al.; The First Synthesis of a Tricyclic Homodetic Peptide Employing Coordinated Orthogonal Protection; Tetrahedron Letters; vol. 37; No. 32; 1996; p. 5637-5640.
Ralph Hirschmann, K.C. nicolaou, Sherrie Pientranico, Joseph Salvino, Ellen M. Leahy, Paul A. Sprengeler, George Furst, Catherine D. Strader, Amos B. Smith III; Nonpeptidal peptidomimetics with .beta.-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist; J. Am. Chem. Soc.; 114 (23); 1992; p. 9217-9218.
Raymond H. Boutin and Henry Rapoport; .alpha.-Amino acid derivatives as chiral educts for asymmetric products. Synthesis of sphingosine from .alpha.′-amino-.alpha.,.beta.-ynones; J. Org. Chem.; 51 (26); 1986; p. 5320-5327.
Raymond H. Boutin and Henry Rapoport; .alpha.-Amino acid derivatives as chiral educts for asymmetric products. Synthesis of sphingosine from .alpha.'-amino-.alpha.,.beta.-ynones; J. Org. Chem.; 51 (26); 1986; p. 5320-5327.
Richard F. Borch, Mark D. Bernstein, and H. Dupont Durst; Cyanohydridoborate anion as a selective reducing agent; J. Am. Chem. Soc.; 93 (12); 1971; p. 2897-2904.
Robert O. Hutchins, et al.; Cyanoborohydride. Utility and Applications in Organic Synthesis. A Review; Org. Prep. Proc. Int.; 1979; 11; p. 203-241.
Robyn N. Smith, Neil J. Mann, Anna Braue, Henna Mäkeläinen, and George A. Varigos; The effect of a high-protein, low glycemic-load diet verses a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: A randomized, investigator-masked, controlled trial; the American Academy of Dermatology, Inc.; J. Acad. Dermatol.; vol. 57; No. 2; p. 247-256; 2007.
Roland Kruse, Arno Rütten, Nadine Schweiger, Eva Jakob, Micaela Mathiak, Peter Propping, Elisabeth Mangold, Michele Bisceglia, and Thomas Ruzicka; Frequency of Microsatellite Instability in Unselected Sebaceous Gland Neoplasias and Hyperplasisas; The Journal of Investigative Dermatology; 2003; 120; p. 858.
Ronald C. Bernotas, et al.; The use of triphenylphosphine/diethyl azodicarboxylate (dead) for the cyclization of 1,4- and 1,5-amino alcohols; Tetrahedron Letters; vol. 32; Issue 2; 1991; p. 161-164.
Sabina Quader, Sue E. Boyd, Ian D. Jenkins, and Todd A. Houston; Multisite Modification of Neomycin B: Combined Mitsunobu and Click Chemistry Approach; J. Org. Chem.; 72; 2007; p. 1962-1979.
Sachin S. Bhardwaj, et al.; Lasers and Light Therapy for Acne Vulgaris; Semin Cutan Med Surg; 24; 2005; p. 107-112.
Sam Shuster; Biological Purpose of Acne; The Lancet; 1976; p. 1328-1329.
Shaoxing Chen, et al.; Design and synthesis of a CD4 β-turn mimetic that inhibits human immunodeficiency virus envelope glycoprotein gp120 binding and infection of human lymphocytes; Proc. Natl. Acad. Sci.; vol. 89; 1992; p. 5872-5876.
Shari B. Clarke, Amanda M. Nelson, Rosalyn E. George, and Diane M. Thiboutot; Pharmacologic Modulation of Sebaceous Gland Activity: Mechanisms and Clinical Applications; Dermatol Clin; 25; (2007); p. 137-146.
Simpson, N.B., and Cunliffe, W.J.; Chapter 43. Disorders of the Sebaceous Glans; In: Rooks' Textbook of Dermatologseicy, Burns, D.A.; Breathnach, S.M.; Cox, N.; Griffiths, C.E. (Eds) 7th Ed Blackwell Science, Malden mass, 2004; p. 43. 1-43.75.
Smith, K.R., et al.; Iron status affects human sebocyte survival; J. Investigative Dermatol; 2007a; 127; o, S68; Abstract 408; Society for Investigative Dermatoloy; May 2007; Los Angeles, CA.s.
Spencer Knapp, Jeffrey J. Hale, Margarita Bastos, Audrey Molina, and Kuang Yu Chen; Synthesis of hypusine and other polyamines using dibenzyltriazones for amino protection; J. Org. Chem.; 57 (23); 1992; p. 6239-6256.
Stephen Hanessian, et al.; Design and Synthesis of Conformationally Constrained Amino Acids as Versatile Scaffolds and Peptide Mimetics; Tetrahedron Report No. 426; vol. 53; No. 38; 1997; p. 12789-12854.
Steven Nahm, et al.; N-methoxy-n-methylamides as effective acylating agents; Tetrahedron Letters; vol. 22; Issue 39; 1981; p. 3815-3818.
S-W. Youn, E-S. Park, D-H. Lee, C-H. Huh, and K-C. Park; Does facial sebum excretion really affect the development of acne?; British Journal of Dermatology; 153; 2005; p. 919-924.
T. Arrhenius, et al.; The Chemical Synthesis of Structured Peptides using Covalent Hydrogen-Bond Mimics; Protein Structure, Folding, and Design; 2; 1987; p. 453-465.
Tatjana Haitina, Janis Klovins, Jan Andersson, Robert Fredriksson, Malin C. Lagerström, Dan Larhammar, Earl T. Larson, and Helgi B. Schiöth; Cloning, tissue distribution, pharmacology and three-dimensional modeling of melanocortin receptors 4 and 5 in rainbow trout suggest close evolutionary relationship of these subtypes; Biochem. J.; 2004; 380; p. 475-486.
Tetsto Tsunoda, et al.; Mitsunobu-type Alkylation of p-Toluenesulfonamide. A Convenient New Route to Primary and Secondary Amines; Tetrahedron Letters; vol. 37; No. 14; 1996; p. 2457-2458.
Thody AJ, Cooper MJ, Meddis, D, Bowden PE, Shuster S; Proceedings: The sebaceous gland response to alpha-melanocyte stimulating hormone and testosterone; J. Endcr.; vol. 67; 1975; p. 18P-19P.
Thody, J.J., Shuster, S; Control of sebaceous gland function in the rat by alpha-melanocyte-stimulating hormone; J. Endcr.; vol. 64; Issue 3; 1975; p. 503-510.
Thomas L. Cupps, Raymond H. Boutin, and Henry Rapoport; .alpha.-Amino acids as chiral educts for asymmetric products. The synthesis of .alpha.′-amino-.alpha.,.beta.-ynones; J. Org. Chem.; 50 (21); 1985; p. 3972-3979.
Thomas L. Cupps, Raymond H. Boutin, and Henry Rapoport; .alpha.-Amino acids as chiral educts for asymmetric products. The synthesis of .alpha.'-amino-.alpha.,.beta.-ynones; J. Org. Chem.; 50 (21); 1985; p. 3972-3979.
Tim Graefe, Uwe Wollina, Hans-Joachim Schulz, Walter Burgdorf; Muir-Torre Syndrome-Treatment with Isotretinoin and Interferon Alpha-2a Can Prevent Tumour Development; Dermatology; 200; 2000; p. 331-333.
Tim Graefe, Uwe Wollina, Hans-Joachim Schulz, Walter Burgdorf; Muir-Torre Syndrome—Treatment with Isotretinoin and Interferon Alpha-2a Can Prevent Tumour Development; Dermatology; 200; 2000; p. 331-333.
Tiziana Basile, Allaye Bocoum, Diego Savoia, and Achille Umani-Ronchi; Enantioselective Synthesis of Homoallylic Amines by Addition of Allylmetal Reagents to Imines Derived from (S)-Valine Esters; J. Org. Chem.; 59 (25); 1994; p. 7766-7773.
U.S. Appl. No. 12/391,748, filed Feb. 24, 2009, Mark Blaskovich.
Uday S. Racheria, Yi Liao and Herbert C. Brown; Chiral synthesis via organoboranes. 36. Exceptionally enantioselective allylborations of representative heterocyclic aldehydes at −100 .degree.C under salt-free conditions; J. Org. Chem.; 57 (24); 1992; p. 6614-6617.
Uday S. Racheria, Yi Liao and Herbert C. Brown; Chiral synthesis via organoboranes. 36. Exceptionally enantioselective allylborations of representative heterocyclic aldehydes at -100 .degree.C under salt-free conditions; J. Org. Chem.; 57 (24); 1992; p. 6614-6617.
Ursula Egner, et al.; Turn Mimetics for Peptide Design; Pesticide Science; 1997; p. 95.
V. Bataille, H. Snieder, A.J. MacGregor, P. Sasieni, and T.D. Spector; The Influence of Genetics and Environmental Factors in the Pathogenesis of Acne: A Twin Study of Acne in Women; The Journal of Investigative Dermatology; 2002; 119; p. 1317.
V. Goulden, C.H. Mcgeown, and W.J. Cunliffe; The familial risk of adult acne: a comparison between first-degree relatives of affected and unaffected individuals; British Journal of Dermatology; 141; 1999; p. 297-300.
V. VanRheenen, et al.; An improved catalytic OsO4 oxidation of olefins to -1,2-glycols using tertiary amine oxides as the oxidant; Tetrahedron Letters; vol. 17; Issue 23; 1976; p. 1973-1976.
Vijay Chhajlani, Ruta Muceniece, and Jarl E. S. Wikberg; Molecular Cloning of a Novel Human Melanocortin Receptor; Biochemical and Biophysical Research Comunications; vol. 195, No. 2; 1993; p. 866-873.
W. Szeja; Phase Transfer-Catalyzed Preparation of Oxiranes; Synthesis; 1985; p. 983-985.
W.F. Huffman, et al.; Mimics of Secondary Structural Elements of Peptides and Proteins; Synthetic Peptides; 1989; p. 257-266.
Wenbiao Chen, Michele A. Kelly, Ximena Optiz-Araya, Ruth E. Thomas, Malcolm J. Low, and Roger D. Cone; Exocrine Gland Dysfunction in MC5-R-Deficient Mice: Evidence for Coordinated Regulation of Exocrine Gland Function by Melanocortin Peptides; Cell; vol. 91; Dec. 12, 1997; p. 789-798.
William F. Huffman, et al.; Reverse turn mimics; Peptide Mimetics; 1988; p. 105-108.
Xin Ma, et al.; Synthesis of a Heterocyclic γ-Turn Peptidomimetic Sequence; Propt Pept Lett; 1995; p. 347-350.
Yoshiniori Yamamoto and Naoki Asao; Selective reactions using allylic metals; Chem. Rev.; 1993; 93 (6); p. 2207-2293.
Zahra Fathi, et al.; Cloning, Expression, and Tissue Distribution of a Fifth Melanocortin Receptor Subtype; Neurochemical Research; vol. 20; No. 1; 1995; p. 107-113.
Zouboulis ChC, Böhm M.; Neuroendocrine regulation of sebocytes-a pathogenetic link between stress and acne; Exp. Dermatol; 13 (Suppl. 4); 2004; p. 31-35.
Zouboulis ChC, Böhm M.; Neuroendocrine regulation of sebocytes—a pathogenetic link between stress and acne; Exp. Dermatol; 13 (Suppl. 4); 2004; p. 31-35.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140128380A1 (en) * 2009-02-27 2014-05-08 Mimetica Pty Ltd Methods of modulating the activity of the mc1 receptor and treatment of conditions related to this receptor

Also Published As

Publication number Publication date
AU2009219106B2 (en) 2013-09-26
NZ587363A (en) 2012-06-29
CA2716250C (en) 2016-02-16
CN102007105B (zh) 2014-09-03
KR20100122102A (ko) 2010-11-19
ES2445456T3 (es) 2014-03-03
HK1148730A1 (en) 2011-09-16
AU2009219106A1 (en) 2009-09-03
IL207700A (en) 2017-01-31
EP2257534A4 (en) 2011-05-04
WO2009105823A1 (en) 2009-09-03
PT2257534E (pt) 2014-02-17
EP2257534B1 (en) 2013-11-06
JP2011513244A (ja) 2011-04-28
BRPI0907903A2 (pt) 2020-08-18
KR101620114B1 (ko) 2016-05-12
IL207700A0 (en) 2010-12-30
JP5503557B2 (ja) 2014-05-28
DK2257534T3 (da) 2014-02-03
RU2010137034A (ru) 2012-04-10
BRPI0907903B1 (pt) 2021-11-09
RU2530017C2 (ru) 2014-10-10
EP2257534A1 (en) 2010-12-08
CN102007105A (zh) 2011-04-06
US20090221557A1 (en) 2009-09-03
MX2010009487A (es) 2011-03-02
CA2716250A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
EP2257297B1 (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
US8008291B2 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US9340517B2 (en) Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8440653B2 (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8343958B2 (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
HK1148730B (en) 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
HK1149187B (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
HK1149187A (en) Compounds for use in the treatment of acne, seborrhoea and sebhorroeic dermatitis, or for reducing sebum secretion
HK1149255B (en) 3-substituted-1,4-diazepan-2-one melanocortin-5 receptor antagonists

Legal Events

Date Code Title Description
AS Assignment

Owner name: MIMETICA PTY LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLASKOVICH, MARK ARNOLD THOMAS;CASSIDY, PETER JOSEPH;REEL/FRAME:026385/0644

Effective date: 20090224

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: MARP THERAPEUTICS PTY LTD, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MIMETICA PTY LTD;REEL/FRAME:059199/0649

Effective date: 20211217

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12